

Gilles A Salles

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6961003/publications.pdf>

Version: 2024-02-01

904
papers

59,413
citations

1099

112
h-index

1424

221
g-index

935
all docs

935
docs citations

935
times ranked

35215
citing authors

#	ARTICLE	IF	CITATIONS
1	The 2016 revision of the World Health Organization classification of lymphoid neoplasms. <i>Blood</i> , 2016, 127, 2375-2390.	1.4	5,965
2	CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2002, 346, 235-242.	27.0	4,928
3	Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2019, 380, 45-56.	27.0	2,594
4	Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. <i>Blood</i> , 2002, 99, 754-758.	1.4	1,819
5	Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , 2005, 23, 4117-4126.	1.6	1,316
6	Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. <i>Lancet</i> , The, 2011, 377, 42-51.	13.7	957
7	PI3KÎ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma. <i>New England Journal of Medicine</i> , 2014, 370, 1008-1018.	27.0	956
8	The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. <i>Blood</i> , 2003, 102, 3871-3879.	1.4	793
9	Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. <i>Blood</i> , 2005, 105, 1851-1861.	1.4	778
10	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet</i> , The, 2019, 393, 229-240.	13.7	517
11	Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. <i>Blood</i> , 2001, 97, 101-106.	1.4	506
12	Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. <i>Blood</i> , 2000, 95, 802-806.	1.4	484
13	Phase III Trial of Consolidation Therapy With Yttrium-90â€“Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 5156-5164.	1.6	431
14	Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease. <i>New England Journal of Medicine</i> , 2007, 357, 1916-1927.	27.0	412
15	Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. <i>Advances in Therapy</i> , 2017, 34, 2232-2273.	2.9	407
16	Survival Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkinâ€™s Lymphoma: Final Analysis of the Prospective LNH87â€™2 Protocolâ€™A Groupe dâ€™Etude des Lymphomes de lâ€™Adulte Study. <i>Journal of Clinical Oncology</i> , 2000, 18, 3025-3030.	1.6	400
17	Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naïve chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. <i>Lancet</i> , The, 2020, 395, 1278-1291.	13.7	393
18	Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. <i>Blood</i> , 2006, 107, 3053-3057.	1.4	390

#	ARTICLE	IF	CITATIONS
19	Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2021, 384, 842-858.	27.0	388
20	Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients.. <i>Journal of Clinical Oncology</i> , 1997, 15, 1624-1630.	1.6	373
21	Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. <i>Lancet Oncology</i> , The, 2016, 17, 200-211.	10.7	373
22	Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). <i>Nature Genetics</i> , 1999, 22, 63-68.	21.4	356
23	Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. <i>Lancet Oncology</i> , The, 2012, 13, 196-206.	10.7	349
24	Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. <i>Lancet Haematology</i> , the, 2016, 3, e196-e204.	4.6	344
25	Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. <i>Lancet</i> , The, 2016, 388, 565-575.	13.7	328
26	Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 978-988.	10.7	320
27	Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 1250-1260.	27.0	313
28	Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNHO3-2B): an open-label randomised phase 3 trial. <i>Lancet</i> , The, 2011, 378, 1858-1867.	13.7	311
29	Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1433-1442.	10.7	306
30	Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. <i>Blood</i> , 2008, 112, 4824-4831.	1.4	304
31	Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2014, 32, 1066-1073.	1.6	304
32	Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1081-1093.	10.7	297
33	Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. <i>Leukemia</i> , 2007, 21, 207-214.	7.2	292
34	Subclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma in Adults. <i>Journal of Clinical Oncology</i> , 2004, 22, 1864-1871.	1.6	289
35	Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients.. <i>Journal of Clinical Oncology</i> , 1997, 15, 1587-1594.	1.6	283
36	Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. <i>Blood</i> , 2000, 95, 1950-1956.	1.4	279

#	ARTICLE	IF	CITATIONS
37	Improved reliability of lymphoma diagnostics via PCR-based clonality testing: Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. <i>Leukemia</i> , 2007, 21, 201-206.	7.2	279
38	Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 351-363.	27.0	278
39	Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. <i>Lancet Oncology</i> , 2015, 16, 704-715.	10.7	272
40	Immunohistochemical Prognostic Markers in Diffuse Large B-Cell Lymphoma: Validation of Tissue Microarray As a Prerequisite for Broad Clinical Applications—A Study From the Lunenburg Lymphoma Biomarker Consortium. <i>Journal of Clinical Oncology</i> , 2007, 25, 805-812.	1.6	271
41	Prognostic significance of survivin expression in diffuse large B-cell lymphomas. <i>Blood</i> , 2000, 96, 1921-5.	1.4	268
42	Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. <i>New England Journal of Medicine</i> , 2018, 379, 934-947.	27.0	264
43	Genetic Polymorphisms in the Tumor Necrosis Factor Locus Influence Non-Hodgkin's Lymphoma Outcome. <i>Blood</i> , 1998, 91, 3574-3581.	1.4	263
44	Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. <i>Lancet Oncology</i> , 2013, 14, 525-533.	10.7	257
45	International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). <i>Annals of Oncology</i> , 2017, 28, 1436-1447.	1.2	249
46	Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20 ⁺ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 4462-4469.	1.6	248
47	CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. <i>Blood</i> , 2013, 121, 48-53.	1.4	243
48	International Consensus Conference on High-Dose Therapy With Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: Report of the Jury. <i>Journal of Clinical Oncology</i> , 1999, 17, 423-423.	1.6	237
49	Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. <i>Lancet Oncology</i> , 2022, 23, 91-103.	10.7	236
50	A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. <i>Blood</i> , 2016, 127, 411-419.	1.4	231
51	Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. <i>Journal of Clinical Oncology</i> , 2016, 34, 3618-3626.	1.6	231
52	Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GÉLA). <i>Blood</i> , 2006, 108, 2540-2544.	1.4	230
53	Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1959-1970.	1.6	228
54	High Numbers of Tumor-Associated Macrophages Have an Adverse Prognostic Value That Can Be Circumvented by Rituximab in Patients With Follicular Lymphoma Enrolled Onto the GELA-GOELAMS FL-2000 Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 440-446.	1.6	226

#	ARTICLE	IF	CITATIONS
55	Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1403-1415.	10.7	222
56	Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. <i>Bone Marrow Transplantation</i> , 2016, 51, 51-57.	2.4	216
57	MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. <i>Blood</i> , 2015, 126, 2466-2474.	1.4	212
58	Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3291-3299.	1.6	195
59	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , 2013, 24, 561-576.	1.2	193
60	⁹⁰ Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1977-1983.	1.6	192
61	High CD34+ Cell Counts Decrease Hematologic Toxicity of Autologous Peripheral Blood Progenitor Cell Transplantation. <i>Blood</i> , 1998, 91, 3148-3155.	1.4	186
62	Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 2912-2919.	1.6	185
63	Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). <i>Lancet Haematology</i> , the, 2019, 6, e254-e265.	4.6	184
64	Mantle cell lymphoma: a retrospective study of 121 cases. <i>Leukemia</i> , 1998, 12, 1281-1287.	7.2	182
65	Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study. <i>Clinical Cancer Research</i> , 2016, 22, 2919-2928.	7.0	181
66	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 1096-1101.	4.1	180
67	Positron Emission Tomography-Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants. <i>Journal of Clinical Oncology</i> , 2011, 29, 3194-3200.	1.6	176
68	Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. <i>Blood</i> , 2012, 119, 5126-5132.	1.4	175
69	Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2815-2824.	1.6	173
70	Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. <i>Blood</i> , 2011, 117, 7070-7078.	1.4	168
71	Impact of [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography Response Evaluation in Patients With High Tumor Burden Follicular Lymphoma Treated With Immunochemotherapy: A Prospective Study From the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. <i>Journal of Clinical Oncology</i> , 2012, 30, 4317-4322.	1.6	168
72	Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 536-543.	1.6	168

#	ARTICLE	IF	CITATIONS
73	Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2016, 27, v83-v90.	1.2	166
74	Intensive Salvage Therapy With High-Dose Chemotherapy for Patients With Advanced Hodgkin's Disease in Relapse or Failure After Initial Chemotherapy: Results of the Groupe d'Études des Lymphomes de l'Adulte H89 Trial. <i>Journal of Clinical Oncology</i> , 2002, 20, 467-475.	1.6	165
75	A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. <i>Lancet Oncology</i> , The, 2018, 19, 549-561.	10.7	165
76	Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. <i>Blood</i> , 2004, 103, 3529-3534.	1.4	162
77	Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. <i>Lancet Oncology</i> , The, 2003, 4, 95-103.	10.7	161
78	Prognostic Significance of <i>MYC</i> Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. <i>Journal of Clinical Oncology</i> , 2019, 37, 3359-3368.	1.6	161
79	CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. <i>Blood</i> , 2021, 138, 2499-2513.	1.4	160
80	International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. <i>Blood</i> , 2020, 135, 2041-2048.	1.4	158
81	Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. <i>Lancet</i> , The, 2016, 387, 2402-2411.	13.7	157
82	Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. <i>Journal of Clinical Oncology</i> , 2017, 35, 2008-2017.	1.6	155
83	Treatment of Splenic Marginal Zone B-Cell Lymphoma: An Analysis of 81 Patients. <i>Clinical Lymphoma and Myeloma</i> , 2002, 3, 41-47.	2.1	148
84	Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. <i>Journal of Clinical Oncology</i> , 2017, 35, 2473-2481.	1.6	148
85	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. <i>Nature Genetics</i> , 2014, 46, 1233-1238.	21.4	147
86	Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. <i>British Journal of Haematology</i> , 1998, 103, 235-241.	2.5	144
87	Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). <i>Annals of Oncology</i> , 2005, 16, 1675-1682.	1.2	144
88	Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity?. <i>Blood</i> , 2008, 111, 2253-2260.	1.4	144
89	Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 1905-1912.	1.6	143
90	Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. <i>Blood</i> , 2014, 124, 3228-3236.	1.4	142

#	ARTICLE	IF	CITATIONS
91	Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2575-2582.	1.6	142
92	Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. <i>Journal of Clinical Oncology</i> , 2019, 37, 144-152.	1.6	142
93	Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. <i>Lancet Haematology</i> , 2014, 1, e17-e27.	4.6	138
94	Risk-Adapted Salvage Treatment With Single or Tandem Autologous Stem-Cell Transplantation for First Relapse/Refractory Hodgkin's Lymphoma: Results of the Prospective Multicenter H96 Trial by the GELA/SFGM Study Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 5980-5987.	1.6	137
95	Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 2920-2926.	1.6	137
96	A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 4127-4137.	7.0	135
97	Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. <i>Oncogene</i> , 2006, 25, 1560-1570.	5.9	132
98	Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: An Updated Systematic Review and Meta-analysis of Randomized Trials. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1799-1806.	6.3	131
99	Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. <i>Haematologica</i> , 2013, 98, 1726-1731.	3.5	131
100	Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. <i>Leukemia</i> , 2015, 29, 1578-1586.	7.2	131
101	Nonfollicular small B-cell lymphomas: a heterogeneous group of patients with distinct clinical features and outcome. <i>Blood</i> , 1994, 83, 2829-2835.	1.4	130
102	High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. <i>Blood</i> , 2015, 126, 604-611.	1.4	130
103	A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. <i>Blood</i> , 2018, 132, 49-58.	1.4	130
104	Aggressive primary gastrointestinal lymphomas: review of 91 patients treated with the LNH-84 regimen. a study of the groupe d'etude des lymphomes agressifs. <i>American Journal of Medicine</i> , 1991, 90, 77-84.	1.5	129
105	Intensive Salvage Therapy With High-Dose Chemotherapy for Patients With Advanced Hodgkin's Disease in Relapse or Failure After Initial Chemotherapy: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. <i>Journal of Clinical Oncology</i> , 2002, 20, 467-475.	1.6	127
106	Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. <i>Blood</i> , 2004, 103, 2727-2737.	1.4	127
107	High burden of BK virus-associated hemorrhagic cystitis in patients undergoing allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 664-670.	2.4	123
108	Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. <i>Blood</i> , 2010, 116, 1092-1104.	1.4	122

#	ARTICLE	IF	CITATIONS
109	Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. <i>Annals of Oncology</i> , 2008, 19, 774-779.	1.2	120
110	Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). <i>Blood</i> , 2013, 122, 1137-1143.	1.4	120
111	High total metabolic tumor volume at baseline predicts survival independent of response to therapy. <i>Blood</i> , 2020, 135, 1396-1405.	1.4	119
112	Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). <i>Blood</i> , 1996, 87, 265-272.	1.4	119
113	Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. <i>Blood</i> , 2010, 116, 4777-4782.	1.4	118
114	t(14;18) Translocation: A Predictive Blood Biomarker for Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 1347-1355.	1.6	115
115	Human germinal center transcriptional programs are de-synchronized in B cell lymphoma. <i>Nature Immunology</i> , 2018, 19, 1013-1024.	14.5	115
116	Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia. <i>Blood</i> , 2008, 111, 2388-2391.	1.4	114
117	Angioimmunoblastic T-Cell Lymphoma. <i>Medicine (United States)</i> , 2007, 86, 282-292.	1.0	113
118	Immunofluorescence In Situ Hybridization Index Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A GELA Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 5573-5579.	1.6	113
119	Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. <i>Annals of Oncology</i> , 2018, 29, 715-723.	1.2	110
120	A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D2); Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.8	110
121	Plasma Cytokine and Soluble Receptor Signature Predicts Outcome of Patients With Classical Hodgkin's Lymphoma: A Study From the Groupe d'Etude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , 2007, 25, 1732-1740.	1.6	108
122	From genetics to the clinic: a translational perspective on follicular lymphoma. <i>Nature Reviews Cancer</i> , 2018, 18, 224-239.	28.4	108
123	Lymphoma Recurrence 5 Years or Later Following Diffuse Large B-Cell Lymphoma: Clinical Characteristics and Outcome. <i>Journal of Clinical Oncology</i> , 2010, 28, 2094-2100.	1.6	107
124	Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 2259-2266.	1.6	107
125	Efficacy and safety of CD19-directed CAR cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials. <i>American Journal of Hematology</i> , 2021, 96, 1295-1312.	4.1	107
126	Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma. <i>Experimental Hematology</i> , 2000, 28, 858-870.	0.4	104

#	ARTICLE	IF	CITATIONS
127	Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. <i>Blood</i> , 2019, 133, 1964-1976.	1.4	104
128	Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.. <i>Journal of Clinical Oncology</i> , 1997, 15, 499-508.	1.6	103
129	The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association. <i>Clinical Cancer Research</i> , 2015, 21, 3428-3435.	7.0	101
130	Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1bâ€“2 study. <i>Lancet Oncology</i> , The, 2019, 20, 998-1010.	10.7	101
131	Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. <i>Haematologica</i> , 2011, 96, 1128-1135.	3.5	99
132	Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. <i>Haematologica</i> , 2013, 98, 1014-1021.	3.5	98
133	The Lymphoid Variant of Hypereosinophilic Syndrome. <i>Medicine (United States)</i> , 2014, 93, 255-266.	1.0	98
134	ELEVATED CIRCULATING LEVELS OF TNFÎ± AND ITS p55 SOLUBLE RECEPTOR ARE ASSOCIATED WITH AN ADVERSE PROGNOSIS IN LYMPHOMA PATIENTS. <i>British Journal of Haematology</i> , 1996, 93, 352-359.	2.5	97
135	A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases. <i>Histopathology</i> , 2006, 48, 162-173.	2.9	97
136	Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3109-3117.	1.6	97
137	Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTCâ€“GELA H8 randomised controlled trial. <i>Lancet Oncology</i> , The, 2009, 10, 1160-1170.	10.7	96
138	Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. <i>American Journal of Human Genetics</i> , 2014, 95, 462-471.	6.2	96
139	The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. <i>Leukemia</i> , 2008, 22, 1917-1924.	7.2	95
140	Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 1603-1610.	1.6	93
141	Early Steps of Follicular Lymphoma Pathogenesis. <i>Advances in Immunology</i> , 2011, 111, 1-46.	2.2	91
142	Gemcitabine as a single agent in the treatment of relapsed or refractory lowâ€“grade nonâ€“Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2001, 113, 772-778.	2.5	90
143	Commercial <sc>antiâ€“CD19 CAR</sc> T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center. <i>American Journal of Hematology</i> , 2020, 95, 1324-1333.	4.1	89
144	Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. <i>Blood Advances</i> , 2020, 4, 560-572.	5.2	88

#	ARTICLE	IF	CITATIONS
145	Tumor necrosis factor $\hat{\pm}$ release is a major biological event associated with rituximab treatment. The Hematology Journal, 2001, 2, 378-384.	1.4	88
146	Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. Journal of Clinical Oncology, 2017, 35, 552-560.	1.6	87
147	Peripheral blood natural killer cell count is associated with clinical outcome in patients with aalPI 2 $\hat{\pm}$ 3 diffuse large B-cell lymphoma. Annals of Oncology, 2007, 18, 1209-1215.	1.2	86
148	p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Annals of Oncology, 2002, 13, 1108-1115.	1.2	84
149	Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplantation, 2004, 33, 921-923.	2.4	84
150	Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. Haematologica, 2011, 96, 1136-1143.	3.5	84
151	Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs. BMC Cancer, 2011, 11, 478.	2.6	84
152	Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. Leukemia and Lymphoma, 2014, 55, 1854-1860.	1.3	83
153	Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors. Blood, 2009, 114, 3173-3180.	1.4	82
154	Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P $\hat{\pm}$ Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases. Clinical Cancer Research, 2017, 23, 2232-2244.	7.0	82
155	Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. Journal of Clinical Oncology, 2018, 36, 2405-2412.	1.6	81
156	Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica, 2021, 106, 2417-2426.	3.5	81
157	CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases. Haematologica, 2010, 95, 604-612.	3.5	80
158	Young Patients With Non $\hat{\pm}$ Germinal Center B-Cell $\hat{\pm}$ Like Diffuse Large B-Cell Lymphoma Benefit From Intensified Chemotherapy With ACVBP Plus Rituximab Compared With CHOP Plus Rituximab: Analysis of Data From the Groupe d'Etudes des Lymphomes de l'Adulte/Lymphoma Study Association Phase III Trial LNH 03-2B. Journal of Clinical Oncology, 2014, 32, 3996-4003.	1.6	79
159	Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B $\hat{\pm}$ cell lymphoma. American Journal of Hematology, 2016, 91, 923-930.	4.1	79
160	A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood, 2021, 137, 600-609.	1.4	79
161	Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood, 2002, 100, 3037-3040.	1.4	78
162	Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia. Blood, 2016, 128, 1625-1630.	1.4	78

#	ARTICLE	IF	CITATIONS
163	Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. <i>Blood Advances</i> , 2022, 6, 533-543.	5.2	77
164	Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. <i>Haematologica</i> , 2012, 97, 1594-1602.	3.5	76
165	Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 572-580.	1.6	76
166	Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 251-267.	2.8	75
167	Frequency and significance of anemia in non-Hodgkin's lymphoma patients. <i>Annals of Oncology</i> , 1998, 9, 1109-1115.	1.2	74
168	Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. <i>Lancet Haematology</i> , 2018, 5, e359-e367.	4.6	74
169	Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. <i>Blood</i> , 2017, 129, 2616-2623.	1.4	73
170	Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 248-256.	1.6	73
171	Two new miR-16 targets: caprin and HMGA1, proteins implicated in cell proliferation. <i>Biology of the Cell</i> , 2009, 101, 511-524.	2.0	71
172	Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. <i>Haematologica</i> , 2013, 98, 1107-1114.	3.5	70
173	Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT. <i>Blood</i> , 2013, 121, 2529-2532.	1.4	70
174	EZH2 alterations in follicular lymphoma: biological and clinical correlations. <i>Blood Cancer Journal</i> , 2017, 7, e555-e555.	6.2	70
175	The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal (G-VDJ) sequences at diagnosis in patients with follicular lymphoma. <i>Oncotarget</i> , 2017, 8, 8765-8774.	1.8	69
176	Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies. <i>Blood</i> , 1993, 82, 3539-3547.	1.4	68
177	CLLD8/KMT1F Is a Lysine Methyltransferase That Is Important for Chromosome Segregation. <i>Journal of Biological Chemistry</i> , 2010, 285, 20234-20241.	3.4	68
178	Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. <i>Blood</i> , 2017, 129, 3037-3039.	1.4	68
179	Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. <i>Haematologica</i> , 2017, 102, e156-e159.	3.5	68
180	Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance. <i>Blood</i> , 2010, 115, 2420-2429.	1.4	67

#	ARTICLE	IF	CITATIONS
181	The European Hematology Association Roadmap for European Hematology Research: a consensus document. <i>Haematologica</i> , 2016, 101, 115-208.	3.5	67
182	Analysis of VH genes in marginal zone lymphoma reveals marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection. <i>Haematologica</i> , 2005, 90, 470-8.	3.5	67
183	Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2011, 22, vi59-vi63.	1.2	66
184	Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy. <i>Blood</i> , 2013, 122, 509-509.	1.4	66
185	Primary Thyroid Lymphoma Is a Heterogeneous Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 105-111.	3.6	65
186	Clinicopathologic Characteristics and Outcome of Diffuse Large B-Cell Lymphomas Presenting With an Associated Low-Grade Component at Diagnosis. <i>Journal of Clinical Oncology</i> , 2006, 24, 5234-5241.	1.6	64
187	Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. <i>Blood</i> , 2015, 126, 2646-2649.	1.4	64
188	Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. <i>Lancet Haematology</i> , 2019, 6, e429-e437.	4.6	64
189	Long-Term Follow-Up of Patients With Newly Diagnosed Follicular Lymphoma in the Prerituximab Era: Effect of Response Quality on Survival—A Study From the Groupe d'Etude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , 2010, 28, 822-829.	1.6	63
190	Clinical Features, Prognosis and Treatment of Follicular Lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2007, 2007, 216-225.	2.5	61
191	Cidofovir in the Treatment of BK Virus-Associated Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 723-730.	2.0	61
192	Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association. <i>Haematologica</i> , 2017, 102, 150-159.	3.5	61
193	Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2019, 43, 341-351.	3.7	61
194	Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. <i>Leukemia</i> , 2007, 21, 1824-1826.	7.2	60
195	Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. <i>Journal of Clinical Oncology</i> , 2015, 33, 1482-1490.	1.6	60
196	Mutational landscape of gray zone lymphoma. <i>Blood</i> , 2021, 137, 1765-1776.	1.4	60
197	Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 369-381.	1.6	60
198	Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients. <i>British Journal of Cancer</i> , 1998, 77, 2357-2362.	6.4	58

#	ARTICLE	IF	CITATIONS
199	Factors That Predict Chemotherapy-Induced Myelosuppression in Lymphoma Patients: Role of the Tumor Necrosis Factor Ligand-Receptor System. <i>Journal of Clinical Oncology</i> , 2000, 18, 325-325.	1.6	58
200	High DNA Methyltransferase DNMT3B Levels: A Poor Prognostic Marker in Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2012, 7, e51527.	2.5	58
201	Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma. <i>Annals of Oncology</i> , 1997, 8, 701-704.	1.2	57
202	Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. <i>Blood</i> , 2012, 120, 2650-2657.	1.4	56
203	Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. <i>American Journal of Hematology</i> , 2020, 95, 510-520.	4.1	56
204	Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. <i>Blood</i> , 2022, 139, 1684-1693.	1.4	56
205	Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux. <i>American Journal of Hematology</i> , 2019, 94, 1314-1324.	4.1	55
206	Cytogenetic analysis delineates a spectrum of chromosomal changes that can distinguish non-MALT marginal zone B-cell lymphomas among mature B-cell entities: a description of 103 cases. <i>Leukemia</i> , 2005, 19, 1818-1823.	7.2	54
207	Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. <i>Annals of Oncology</i> , 2016, 27, 390-397.	1.2	54
208	Exome sequencing identifies recurrent <i>BCOR</i> alterations and the absence of <i>KLF2</i> , <i>TNFAIP3</i> and <i>MYD88</i> mutations in splenic diffuse red pulp small B-cell lymphoma. <i>Haematologica</i> , 2017, 102, 1758-1766.	3.5	54
209	Implication of the folate-methionine metabolism pathways in susceptibility to follicular lymphomas. <i>Blood</i> , 2006, 108, 278-285.	1.4	53
210	Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. <i>European Cytokine Network</i> , 2006, 17, 60-6.	2.0	53
211	Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study. <i>Haematologica</i> , 2007, 92, 1083-1090.	3.5	52
212	The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium. <i>Haematologica</i> , 2014, 99, 715-725.	3.5	52
213	Obinutuzumab in hematologic malignancies: Lessons learned to date. <i>Cancer Treatment Reviews</i> , 2015, 41, 784-792.	7.7	52
214	Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. <i>Human Molecular Genetics</i> , 2016, 25, 1663-1676.	2.9	52
215	Prevalence and pattern of antinuclear autoantibodies in 347 patients with non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2003, 123, 90-99.	2.5	51
216	Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma. <i>Cancer</i> , 2009, 115, 4540-4546.	4.1	51

#	ARTICLE	IF	CITATIONS
217	Cyclin-dependent kinase 1 expression is inhibited by p16INK4a at the post-transcriptional level through the microRNA pathway. <i>Oncogene</i> , 2011, 30, 1880-1891.	5.9	51
218	Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma. <i>Haematologica</i> , 2013, 98, 357-363.	3.5	51
219	Long term outcome of patients with hairy cell leukemia treated with pentostatin. , 1999, 85, 65-71.		50
220	Clinicopathologic Features of Waldenström's Macroglobulinemia and Marginal Zone Lymphoma: Are They Distinct or the Same Entity?. <i>Clinical Lymphoma and Myeloma</i> , 2005, 5, 220-224.	2.1	50
221	Accurate Classification of Germinal Center B-Cell-Like/Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase-Like Multiplex Ligation-Dependent Probe Amplification Assay. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 273-283.	2.8	50
222	Rituximab maintenance improves overall survival of patients with follicular lymphoma—Individual patient data meta-analysis. <i>European Journal of Cancer</i> , 2017, 76, 216-225.	2.8	50
223	Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study. <i>Blood</i> , 2018, 131, 2449-2453.	1.4	49
224	Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier. <i>Blood</i> , 2020, 135, 996-1007.	1.4	49
225	Genetic and phenotypic attributes of splenic marginal zone lymphoma. <i>Blood</i> , 2022, 139, 732-747.	1.4	49
226	Prognostic value of miR-16 expression in childhood acute lymphoblastic leukemia relationships to normal and malignant lymphocyte proliferation. <i>Leukemia Research</i> , 2009, 33, 1217-1223.	0.8	48
227	Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. <i>Annals of Oncology</i> , 2012, 23, 2380-2385.	1.2	48
228	International Prognostic Index, Type of Transplant and Response to Rituximab Are Key Parameters to Tailor Treatment in Adults With CD20-Positive B Cell PTL: Clues From the PTL-1 Trial. <i>American Journal of Transplantation</i> , 2015, 15, 1091-1100.	4.7	48
229	Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059. <i>Blood</i> , 2017, 129, 2808-2810.	1.4	48
230	A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features. <i>Clinical Cancer Research</i> , 2020, 26, 3145-3153.	7.0	48
231	Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 629-637.	5.2	48
232	Translocations involving the short arm of chromosome 17 in chronic B-lymphoid disorders: frequent occurrence of dicentric rearrangements and possible association with adverse outcome. <i>Leukemia</i> , 1999, 13, 460-468.	7.2	47
233	Telomeric damage in early stage of chronic lymphocytic leukemia correlates with shelterin dysregulation. <i>Blood</i> , 2011, 118, 1316-1322.	1.4	47
234	An 18F-FDG-PET maximum standardized uptake value ≥ 10 represents a novel valid marker for discerning Richter's Syndrome. <i>Leukemia and Lymphoma</i> , 2016, 57, 1474-1477.	1.3	47

#	ARTICLE	IF	CITATIONS
235	ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 31-31.	1.4	47
236	Primary cardiac lymphoma: diagnosis, treatment and outcome in a modern series. <i>Hematological Oncology</i> , 2017, 35, 510-519.	1.7	46
237	Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors. <i>American Journal of Medicine</i> , 1999, 106, 191-197.	1.5	45
238	Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2002, 30, 769-775.	2.4	45
239	Identification of circulating CD10 positive T cells in angioimmunoblastic T-cell lymphoma. <i>Leukemia</i> , 2006, 20, 296-303.	7.2	45
240	Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT. <i>Bone Marrow Transplantation</i> , 2016, 51, 212-218.	2.4	45
241	Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. <i>Leukemia</i> , 2020, 34, 2184-2197.	7.2	45
242	Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL. <i>Journal of Clinical Oncology</i> , 2018, 36, 7507-7507.	1.6	45
243	Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group. <i>Haematologica</i> , 2016, 101, 474-481.	3.5	44
244	Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study. <i>Lancet Haematology</i> , 2021, 8, e355-e364.	4.6	43
245	Follicular lymphoma triggers phenotypic and functional remodeling of the human lymphoid stromal cell landscape. <i>Immunity</i> , 2021, 54, 1788-1806.e7.	14.3	43
246	Randomized Phase III Study Comparing an Early PET Driven Treatment De-Escalation to a Not PET-Monitored Strategy in Patients with Advanced Stages Hodgkin Lymphoma: Interim Analysis of the AHL2011 Lysa Study. <i>Blood</i> , 2015, 126, 577-577.	1.4	43
247	Relevance of a scoring system including CD11c expression in the identification of splenic diffuse red pulp small B-cell lymphoma (SRPL). <i>Hematological Oncology</i> , 2011, 29, 47-51.	1.7	42
248	Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma. <i>Leukemia</i> , 2013, 27, 252-255.	7.2	42
249	Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucef (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2020, 136, 40-41.	1.4	42
250	Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucef (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL). <i>Journal of Clinical Oncology</i> , 2020, 38, 8008-8008.	1.6	42
251	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 179-184.	4.1	41
252	Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma. <i>Haematologica</i> , 2017, 102, 2104-2112.	3.5	41

#	ARTICLE	IF	CITATIONS
253	Diffuse large B-cell lymphoma: new targets and novel therapies. <i>Blood Cancer Journal</i> , 2021, 11, 68.	6.2	41
254	Monitoring NK cell activity in patients with hematological malignancies. <i>Oncolimmunology</i> , 2013, 2, e26011.	4.6	40
255	Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets. <i>Blood Advances</i> , 2017, 1, 1884-1890.	5.2	40
256	MALT lymphomas: pathogenesis can drive treatment. <i>Oncology</i> , 2011, 25, 1134-42, 1147.	0.5	40
257	Combined QT Interval and Voltage Criteria Improve Left Ventricular Hypertrophy Detection in Resistant Hypertension. <i>Hypertension</i> , 2005, 46, 1207-1212.	2.7	39
258	Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis. <i>Blood</i> , 2009, 113, 3307-3313.	1.4	39
259	PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 408-415.	6.4	39
260	Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. <i>Haematologica</i> , 2017, 102, 1413-1423.	3.5	39
261	Determination of Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Reverse Transcriptase Multiplex Ligation-Dependent Probe Amplification Classifier. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 892-904.	2.8	39
262	Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older. <i>Journal of Clinical Oncology</i> , 2021, 39, 1203-1213.	1.6	39
263	Cytogenetic and molecular delineation of a region of chromosome 3q commonly gained in marginal zone B-cell lymphoma. <i>Haematologica</i> , 2003, 88, 31-8.	3.5	39
264	Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study. <i>Annals of Oncology</i> , 1999, 10, 1349-1354.	1.2	38
265	Autoimmune thrombocytopenic purpura after autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2003, 32, 89-95.	2.4	38
266	Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group. <i>Blood</i> , 2016, 128, 145-145.	1.4	38
267	Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 8004-8004.	1.6	38
268	Plasma TNF- α and IL-10 Level-Based Prognostic Model Predicts Outcome of Patients with Diffuse Large B-Cell Lymphoma in Different Risk Groups Defined by the International Prognostic Index. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2010, 58, 131-141.	2.3	37
269	Splenic marginal zone B-cell lymphoma. <i>Current Opinion in Oncology</i> , 2011, 23, 441-448.	2.4	37
270	CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder. <i>Haematologica</i> , 2015, 100, 1086-95.	3.5	37

#	ARTICLE	IF	CITATIONS
271	The Tumor Necrosis Factor Signaling Complex: Choosing a Path Toward Cell Death or Cell Proliferation. <i>Leukemia and Lymphoma</i> , 1998, 29, 81-92.	1.3	36
272	Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1898-1907.	1.3	36
273	Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. <i>Cancer</i> , 2005, 104, 1434-1441.	4.1	35
274	Transcriptional Activation of hTERT, the Human Telomerase Reverse Transcriptase, by Nuclear Factor of Activated T Cells. <i>Journal of Biological Chemistry</i> , 2009, 284, 35725-35734.	3.4	35
275	MicroRNA expression profile in splenic marginal zone lymphoma. <i>British Journal of Haematology</i> , 2012, 156, 279-281.	2.5	35
276	A matched case-control study of toxoplasmosis after allogeneic haematopoietic stem cell transplantation: still a devastating complication. <i>Clinical Microbiology and Infection</i> , 2016, 22, 636-641.	6.0	35
277	HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. <i>Cancer Research</i> , 2018, 78, 4086-4096.	0.9	34
278	Allele-specific binding to the -308 single nucleotide polymorphism site in the tumour necrosis factor-alpha promoter. <i>International Journal of Immunogenetics</i> , 2004, 31, 15-19.	1.2	33
279	ABVD or BEACOPP baseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC) Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial. <i>European Journal of Cancer</i> , 2017, 81, 45-55.	2.8	33
280	Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma. <i>Blood</i> , 2019, 134, 123-123.	1.4	33
281	Gene expression profiling of gray zone lymphoma. <i>Blood Advances</i> , 2020, 4, 2523-2535.	5.2	32
282	Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis. <i>British Journal of Haematology</i> , 2014, 164, 659-667.	2.5	31
283	Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma. <i>Haematologica</i> , 2016, 101, 226-234.	3.5	31
284	High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia. <i>World Journal of Stem Cells</i> , 2017, 9, 227-234.	2.8	31
285	Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA. <i>Annals of Oncology</i> , 2013, 24, 2612-2618.	1.2	30
286	Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 275-284.	0.4	30
287	Splenic diffuse red pulp small-B cell lymphoma: toward the emergence of a new lymphoma entity. <i>Discovery Medicine</i> , 2012, 13, 253-65.	0.5	30
288	Inhibition of CD10/neutral endopeptidase 24.11 promotes B-cell reconstitution and maturation in vivo.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 7618-7622.	7.1	29

#	ARTICLE	IF	CITATIONS
289	Outcome in Relation to Treatment Modalities in 48 Patients with Localized Gastric MALT Lymphoma: A Retrospective Study of Patients Treated During 1976-2001. <i>Leukemia and Lymphoma</i> , 2003, 44, 257-262.	1.3	29
290	Maintenance Therapy with a Monthly Injection of Alemtuzumab Prolongs Response Duration in Patients with Refractory B-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (B-CLL/SLL). <i>Leukemia and Lymphoma</i> , 2004, 45, 711-714.	1.3	29
291	CD10 and ICOS expression by multiparametric flow cytometry in angioimmunoblastic T-cell lymphoma. <i>Modern Pathology</i> , 2011, 24, 993-1003.	5.5	29
292	Predictors of prescription errors involving anticancer chemotherapy agents. <i>European Journal of Cancer</i> , 2012, 48, 1192-1199.	2.8	29
293	Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2012, 5, 27.	17.0	29
294	Refining diffuse large B-cell lymphoma subgroups using integrated analysis of molecular profiles. <i>EBioMedicine</i> , 2019, 48, 58-69.	6.1	29
295	On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 468-478.	4.1	29
296	90Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin's Lymphoma: First Results of the International Randomized Phase 3 First-Line Indolent Trial (FIT) in 414 Patients.. <i>Blood</i> , 2007, 110, 643-643.	1.4	29
297	Human $\beta\gamma$ T Cells Express a Higher TCR/CD3 Complex Density Than $\alpha\beta$ T Cells. <i>Clinical Immunology</i> , 2001, 98, 358-363.	3.2	28
298	The superoxide dismutase content in erythrocytes predicts short-term toxicity of high-dose cyclophosphamide. <i>British Journal of Haematology</i> , 2001, 112, 405-409.	2.5	28
299	Telomere uncapping during <i>in vitro</i> T cell lymphocyte senescence. <i>Aging Cell</i> , 2009, 8, 52-64.	6.7	28
300	The t(14;18)(q32;q21)/IGH-MALT1 translocation in MALT lymphomas contains templated nucleotide insertions and a major breakpoint region similar to follicular and mantle cell lymphoma. <i>Blood</i> , 2010, 115, 2214-2219.	1.4	28
301	Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase. <i>Investigational New Drugs</i> , 2014, 32, 795-805.	2.6	28
302	Comparative toxicities of 3 platinum-containing chemotherapy regimens in relapsed/refractory lymphoma patients. <i>Hematological Oncology</i> , 2017, 35, 584-590.	1.7	28
303	Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes. <i>Genetic Epidemiology</i> , 2019, 43, 844-863.	1.3	28
304	Long-Term Follow-up of Tisagenlecleucel in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Updated Analysis of Juliet Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S20-S21.	2.0	28
305	Potential of Circulating Tumor DNA for the Management of Patients With Lymphoma. <i>JCO Oncology Practice</i> , 2020, 16, 561-568.	2.9	28
306	Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel. <i>Blood</i> , 2018, 132, 1684-1684.	1.4	28

#	ARTICLE	IF	CITATIONS
307	Distribution of the cytogenetic abnormality +i(3)(q10) in persistent polyclonal B-cell lymphocytosis: a FICTION study in three cases. <i>British Journal of Haematology</i> , 1997, 99, 531-536.	2.5	27
308	Epileptic seizures after autologous peripheral blood progenitor infusion in a patient treated with high-dose chemotherapy for myeloma. <i>Bone Marrow Transplantation</i> , 2002, 29, 544-544.	2.4	27
309	Hepatitis C virus infection and B-cell non-Hodgkin's lymphoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 1361-1365.	1.6	27
310	Lack of intrafollicular memory CD4 ⁺ T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 130.	6.2	27
311	Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study. <i>Blood</i> , 2018, 132, 782-782.	1.4	27
312	In non-follicular lymphoproliferative disorders, <i>IGH</i> BCL2 fusion is not restricted to chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2012, 158, 489-498.	2.5	26
313	The Biology of Aging and Lymphoma: a Complex Interplay. <i>Current Oncology Reports</i> , 2015, 17, 32.	4.0	26
314	Body mass index and other anthropometric parameters in patients with diffuse large B-cell lymphoma: physiopathological significance and predictive value in the immunochemotherapy era. <i>Leukemia and Lymphoma</i> , 2015, 56, 1959-1968.	1.3	26
315	EPICC study: evaluation of pharmaceutical intervention in cancer care. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015, 40, 196-203.	1.5	26
316	The Need for a Consensus Next-Generation Sequencing Panel for Mature Lymphoid Malignancies. <i>HemaSphere</i> , 2019, 3, e169.	2.7	26
317	Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2014, 124, 4457-4457.	1.4	26
318	Profiles and prognostic values of LDH isoenzymes in patients with non-Hodgkin's lymphoma. <i>Leukemia</i> , 1999, 13, 811-817.	7.2	25
319	Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients. <i>Human Pathology</i> , 2017, 64, 128-136.	2.0	25
320	Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?. <i>Hematological Oncology</i> , 2018, 36, 399-406.	1.7	25
321	An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma. <i>Blood</i> , 2018, 132, 1486-1494.	1.4	25
322	Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells. <i>Clinical Nuclear Medicine</i> , 2021, 46, 627-634.	1.3	25
323	Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial. <i>Blood</i> , 2020, 136, 48-49.	1.4	25
324	International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: Report of the jury. <i>Annals of Oncology</i> , 1999, 10, 13-20.	1.2	24

#	ARTICLE	IF	CITATIONS
325	Distinct chromosome 3 abnormalities in persistent polyclonal B-cell lymphocytosis. , 1999, 26, 221-228.		24
326	T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?. Human Pathology, 2008, 39, 194-200.	2.0	24
327	Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma. Haematologica, 2015, 100, e269-e271.	3.5	24
328	Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. Journal of Clinical Oncology, 2015, 33, 3930-3937.	1.6	24
329	Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. Lancet Haematology, the, 2020, 7, e649-e659.	4.6	24
330	Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma. Expert Opinion on Biological Therapy, 2021, 21, 455-463.	3.1	24
331	RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2021, 27, 6124-6134.	7.0	24
332	CD20-Tcb (RG6026), a Novel "2:1" Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Phase I First in Human Trial. Blood, 2018, 132, 226-226.	1.4	24
333	Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial. Blood, 2019, 134, 1584-1584.	1.4	24
334	Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial. Blood, 2019, 134, 4103-4103.	1.4	24
335	Update of the FL2000 randomized trial combining rituximab to CHVP-Interferon in follicular lymphoma (FL) patients (pts). Journal of Clinical Oncology, 2006, 24, 7508-7508.	1.6	24
336	Second treatment with rituximab in B-cell non-Hodgkin's lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud. The Hematology Journal, 2004, 5, 467-471.	1.4	23
337	Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non-Hodgkin's lymphoma. Genes Chromosomes and Cancer, 2007, 46, 500-507.	2.8	23
338	A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. Annals of Oncology, 2012, 23, 2687-2695.	1.2	23
339	Sequential combination of high dose methotrexate and asparaginase followed by allogeneic transplant: a first-line strategy for CD4+/CD56+ hematodermic neoplasm. Leukemia and Lymphoma, 2012, 53, 1633-1637.	1.3	23
340	Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis. Human Pathology, 2014, 45, 2085-2093.	2.0	23
341	Lenalidomide is safe and active in Waldenström macroglobulinemia. American Journal of Hematology, 2015, 90, 1055-1059.	4.1	23
342	Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines. Scientific Reports, 2015, 5, 8068.	3.3	23

#	ARTICLE	IF	CITATIONS
343	Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1001-1009.	2.4	23
344	Metagenomic Next-Generation Sequencing Reveals Individual Composition and Dynamics of Anelloviruses during Autologous Stem Cell Transplant Recipient Management. <i>Viruses</i> , 2018, 10, 633.	3.3	23
345	R-CHOP14 Compared to R-CHOP21 in Elderly Patients with Diffuse Large B-Cell Lymphoma: Results of the Interim Analysis of the LNH03-6B GELA Study.. <i>Blood</i> , 2009, 114, 406-406.	1.4	23
346	A Retrospective Analysis of Pneumocystis Jirovecii Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials. <i>Blood</i> , 2016, 128, 3705-3705.	1.4	23
347	Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts. <i>Journal of Clinical Oncology</i> , 2023, 41, 541-554.	1.6	23
348	Molecular Classification of Diffuse Large B-cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1163-1177.	2.2	22
349	Carbustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review. <i>Bone Marrow Transplantation</i> , 2017, 52, 941-949.	2.4	22
350	BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab. <i>American Journal of Hematology</i> , 2017, 92, 515-519.	4.1	22
351	Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma. <i>Blood Cancer Journal</i> , 2020, 10, 59.	6.2	22
352	Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study. <i>Blood</i> , 2016, 128, 615-615.	1.4	22
353	Reduced progression-free survival in elderly patients receiving intensification with autologous peripheral blood stem cell reinfusion for multiple myeloma. <i>Bone Marrow Transplantation</i> , 1998, 21, 1037-1041.	2.4	21
354	Genetic polymorphisms in the proximal IL-10 promoter and susceptibility to non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 2235-2238.	1.3	21
355	Current and future management of follicular lymphoma. <i>International Journal of Hematology</i> , 2012, 96, 544-551.	1.6	21
356	BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial. <i>Annals of Oncology</i> , 2017, 28, 1042-1049.	1.2	21
357	Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. <i>Lancet Haematology</i> , 2018, 5, e403-e410.	4.6	21
358	Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B-cell lymphoma, a clinicopathological series of 25 cases. <i>British Journal of Haematology</i> , 2020, 189, 244-256.	2.5	21
359	Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma. <i>Blood</i> , 2021, 137, 2704-2707.	1.4	21
360	Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 4079-4079.	1.4	21

#	ARTICLE	IF	CITATIONS
361	A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM) or solid malignancies (SOL).. Journal of Clinical Oncology, 2015, 33, 3065-3065.	1.6	21
362	Expression of genes coding for the tumor necrosis factor and lymphotoxin ligand-receptor system in non-Hodgkin's lymphomas. Cancer Immunology, Immunotherapy, 2000, 49, 469-475.	4.2	20
363	Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. Lancet Haematology, the, 2019, 6, e470-e479.	4.6	20
364	EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma. Future Oncology, 2021, 17, 2127-2140.	2.4	20
365	Higher LPS-stimulated TNF- α mRNA levels in peripheral blood mononuclear cells from non-Hodgkin's lymphoma patients. Experimental Hematology, 2001, 29, 330-338.	0.4	19
366	Prevalence of Anticentromere F Protein Autoantibodies in 347 Patients with Non-Hodgkin's Lymphoma. Annals of the New York Academy of Sciences, 2005, 1050, 319-326.	3.8	19
367	Cytogenetic and Molecular Analysis of 12 Cases of Primary Cutaneous Marginal Zone Lymphomas. American Journal of Dermatopathology, 2006, 28, 287-292.	0.6	19
368	Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma. Cancer Chemotherapy and Pharmacology, 2008, 61, 855-863.	2.3	19
369	Hairy cell leukaemia—variant and splenic red pulp lymphoma: a single entity?. British Journal of Haematology, 2010, 150, 113-115.	2.5	19
370	Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study. Leukemia and Lymphoma, 2010, 51, 399-405.	1.3	19
371	Targeting netrin-1/DCC interaction in diffuse large B-cell and mantle cell lymphomas. EMBO Molecular Medicine, 2016, 8, 96-104.	6.9	19
372	CD1d-restricted peripheral T cell lymphoma in mice and humans. Journal of Experimental Medicine, 2016, 213, 841-857.	8.5	19
373	Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials. Leukemia, 2016, 30, 1428-1430.	7.2	19
374	FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e545-e550.	0.4	19
375	Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a Lysa Study. Blood, 2014, 124, 146-146.	1.4	19
376	A New Death Receptor 3 Isoform: Expression in Human Lymphoid Cell Lines and Non-Hodgkin's Lymphomas. Biochemical and Biophysical Research Communications, 1998, 242, 376-379.	2.1	18
377	Suspicion of Drug-Drug Interaction between High-Dose Methotrexate and Proton Pump Inhibitors: A Case Report — Should the Practice Be Changed?. Chemotherapy, 2011, 57, 225-229.	1.6	18
378	μ -Calpain Conversion of Antiapoptotic Bfl-1 (BCL2A1) into a Prodeath Factor Reveals Two Distinct alpha-Helices Inducing Mitochondria-Mediated Apoptosis. PLoS ONE, 2012, 7, e38620.	2.5	18

#	ARTICLE	IF	CITATIONS
379	A restricted IGHV gene repertoire in splenic marginal zone lymphoma is associated with autoimmune disorders. <i>Haematologica</i> , 2014, 99, e197-e198.	3.5	18
380	A high rate of telomeric sister chromatid exchange occurs in chronic lymphocytic leukaemia B-cells. <i>British Journal of Haematology</i> , 2016, 174, 57-70.	2.5	18
381	Splenic diffuse red pulp lymphoma has a distinct pattern of somatic mutations amongst B-cell malignancies. <i>Leukemia and Lymphoma</i> , 2017, 58, 666-675.	1.3	18
382	Validation of the prognostic value of the knowledge bank approach to determine AML prognosis in real life. <i>Blood</i> , 2018, 132, 865-867.	1.4	18
383	A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Relapsed/Refractory DLBCL. <i>Blood</i> , 2014, 124, 628-628.	1.4	18
384	Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study. <i>Blood</i> , 2022, 139, 2338-2346.	1.4	18
385	Anaphylactoid reaction with bronchospasm following intravenous cyclophosphamide administration. <i>Annals of Hematology</i> , 1991, 62, 74-75.	1.8	17
386	Multifocal progressive leukoencephalopathy occurring after refractory anemia and multiple infectious disorders consecutive to severe lymphopenia. <i>Annals of Hematology</i> , 2002, 81, 340-342.	1.8	17
387	Lentiviral vectors and transduction of human cancer B cells. <i>Blood</i> , 2010, 116, 498-500.	1.4	17
388	Are We Nearing an Era of Chemotherapy-Free Management of Indolent Lymphoma?. <i>Clinical Cancer Research</i> , 2014, 20, 5226-5239.	7.0	17
389	TREATMENT WITH LOW-DOSE CYTARABINE IN ELDERLY PATIENTS (AGE 70 YEARS OR OLDER) WITH ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION EXPERIENCE. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 8, 2016009.	1.3	17
390	Successful pregnancies in patients with BCR-ABL positive leukemias treated with interferon-alpha therapy during the tyrosine kinase inhibitors era. <i>European Journal of Haematology</i> , 2018, 101, 774-780.	2.2	17
391	Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways. <i>Human Molecular Genetics</i> , 2020, 29, 70-79.	2.9	17
392	Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306). <i>British Journal of Haematology</i> , 2020, 188, 240-248.	2.5	17
393	Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension. <i>Blood</i> , 2020, 136, 17-19.	1.4	17
394	Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 4393-4393.	1.4	17
395	Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: Results from two independent cohorts. <i>Cytokine</i> , 2013, 64, 523-531.	3.2	16
396	Treatment Approach to Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Seminars in Hematology</i> , 2015, 52, 107-118.	3.4	16

#	ARTICLE	IF	CITATIONS
397	Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay. <i>Haematologica</i> , 2017, 102, e404-e406.	3.5	16
398	Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review. <i>Leukemia and Lymphoma</i> , 2019, 60, 1610-1625.	1.3	16
399	Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study. <i>Leukemia</i> , 2019, 33, 776-780.	7.2	16
400	Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study. <i>Blood Advances</i> , 2020, 4, 3217-3223.	5.2	16
401	Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1079-1088.	4.1	16
402	Phase I Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2009, 114, 1704-1704.	1.4	16
403	Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8519-8519.	1.6	16
404	Skin Lesions in Malignancy. <i>Journal of Clinical Oncology</i> , 2001, 19, 2100-2101.	1.6	15
405	Asymptomatic bone marrow involvement in patients presenting with cutaneous marginal zone B-cell lymphoma. <i>British Journal of Dermatology</i> , 2008, 159, 498-500.	1.5	15
406	S-phase lengthening induced by p16INK4a overexpression in malignant cells with wild-type pRb and p53. <i>Cell Cycle</i> , 2010, 9, 3306-3316.	2.6	15
407	Usual and unusual pitfalls of 18F-FDG-PET/CT in lymphoma after treatment. <i>Nuclear Medicine Communications</i> , 2017, 38, 563-576.	1.1	15
408	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. <i>Lupus Science and Medicine</i> , 2017, 4, e000187.	2.7	15
409	One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 704.	4.8	15
410	Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Brutonâ€™s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059). <i>Leukemia</i> , 2020, 34, 1458-1461.	7.2	15
411	Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, 35, 1597-1609.	7.2	15
412	High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3B. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1324-1336.	3.7	15
413	Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?. <i>Blood Advances</i> , 2021, 5, 4185-4197.	5.2	15
414	Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel. <i>Blood</i> , 2019, 134, 2883-2883.	1.4	15

#	ARTICLE	IF	CITATIONS
415	Clinical Activity of Abemaciclib (LY2835219), a Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Relapsed or Refractory Mantle Cell Lymphoma. <i>Blood</i> , 2014, 124, 3067-3067.	1.4	15
416	Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses at lower dose level.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8503-8503.	1.6	15
417	Baseline total metabolic volume (TMTV) to predict the outcome of patients with advanced Hodgkin lymphoma (HL) enrolled in the AHL2011 LYSA trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7509-7509.	1.6	15
418	Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. <i>Clinical Cancer Research</i> , 2022, 28, 4003-4017.	7.0	15
419	Toxicities after peripheral blood progenitor cell transplantation for lymphoid malignancies: analysis of 300 cases in a single institution. <i>Bone Marrow Transplantation</i> , 1999, 23, 1309-1315.	2.4	14
420	Autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 1999, 12, 151-169.	1.7	14
421	Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment. <i>Annals of Oncology</i> , 2008, 19, 1485-1487.	1.2	14
422	Administration of Anticancer Drugs: Exposure in Hospital Nurses. <i>Clinical Therapeutics</i> , 2014, 36, 401-407.	2.5	14
423	Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma. <i>Haematologica</i> , 2015, 100, e204-e206.	3.5	14
424	Prognostic Value of Genetic Alterations in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience. <i>Cancers</i> , 2019, 11, 570.	3.7	14
425	Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study. <i>Cancer</i> , 2019, 125, 2291-2299.	4.1	14
426	Efficacy and Safety of Revaccination against Tetanus, Diphtheria, Haemophilus influenzae Type b and Hepatitis B Virus in a Prospective Cohort of Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1729-1737.	2.0	14
427	Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies. <i>Blood</i> , 2018, 132, 228-228.	1.4	14
428	Evaluation of complete response rate at 30 months (CR30) as a surrogate for progression-free survival (PFS) in first-line follicular lymphoma (FL) studies: Results from the prospectively specified Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) analysis with individual patient data (IPD) of 3,837 patients (pts).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8504-8504.	1.6	14
429	Neutrophils protect lymphoma cells against cytotoxic and targeted therapies through CD11b/ICAM-1 binding. <i>Oncotarget</i> , 2017, 8, 72818-72834.	1.8	14
430	Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1 "Clinical"). <i>Journal of Nuclear Medicine</i> , 2023, 64, 102-108.	5.0	14
431	Heterogeneity of acute lymphoblastic leukemia in HIV-seropositive patients. <i>Annals of Oncology</i> , 1994, 5, 437-440.	1.2	13
432	Inherited cytokine response and risk of lymphoma. <i>Lancet Oncology</i> , The, 2006, 7, 3-4.	10.7	13

#	ARTICLE	IF	CITATIONS
433	Transfusion dependency at diagnosis and transfusion intensity during initial chemotherapy are associated with poorer outcomes in adult acute myeloid leukemia. <i>Annals of Hematology</i> , 2015, 94, 1797-1806.	1.8	13
434	Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies. <i>Leukemia and Lymphoma</i> , 2016, 57, 2820-2826.	1.3	13
435	Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA. <i>Annals of Oncology</i> , 2016, 27, 1349-1350.	1.2	13
436	Global Pivotal Phase 2 Trial of the CD19-Targeted Therapy CTL019 In Adult Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) – An Interim Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S373-S374.	0.4	13
437	A susceptibility locus for classical Hodgkin lymphoma at 8q24 near <i>MYC</i> predicts patient outcome in two independent cohorts. <i>British Journal of Haematology</i> , 2018, 180, 286-290.	2.5	13
438	Lipid Trait Variants and the Risk of Non-Hodgkin Lymphoma Subtypes: A Mendelian Randomization Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1074-1078.	2.5	13
439	Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas. <i>Leukemia and Lymphoma</i> , 2021, 62, 1077-1087.	1.3	13
440	Rituximab Combined with Chemotherapy and Interferon in Follicular Lymphoma Patients: Final Analysis of the GELA-GOELAMS FL2000 Study with a 5-Year Follow-Up.. <i>Blood</i> , 2007, 110, 792-792.	1.4	13
441	RCHOP and RDHAP Followed by Autologous Stem Cell Transplantation (ASCT) in Mantle Cell Lymphoma (MCL) : Final Results of a Phase II Study from the GELA. <i>Blood</i> , 2008, 112, 581-581.	1.4	13
442	Phase I Study of Escalating Doses of Lenalidomide Combined with R-CHOP (R2-CHOP) for Front-Line Treatment of B-Cell Lymphomas. <i>Blood</i> , 2011, 118, 1632-1632.	1.4	13
443	Phase I/IIb Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring. <i>Clinical Cancer Research</i> , 2022, 28, 45-56.	7.0	13
444	Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma. <i>Leukemia</i> , 2021, 35, 2108-2113.	7.2	13
445	Prospects in the management of patients with follicular lymphoma beyond first-line therapy. <i>Haematologica</i> , 2022, 107, 19-34.	3.5	13
446	CD40 regulation of death domains containing receptors and their ligands on lymphoma B cells. <i>British Journal of Haematology</i> , 1998, 103, 684-689.	2.5	12
447	Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2004, 104, 1584-1586.	1.4	12
448	Recurrent cerebral venous thrombosis revealing paraneoplastic angiitis in Hodgkin's lymphoma. <i>Journal of Neuro-Oncology</i> , 2008, 89, 195-198.	2.9	12
449	Prognostic Systems for Lymphomas. <i>Hematology/Oncology Clinics of North America</i> , 2008, 22, 839-861.	2.2	12
450	Immunoarchitectural patterns in splenic marginal zone lymphoma: correlations with chromosomal aberrations, <i>IGHV</i> mutations, and survival. A study of 76 cases. <i>Histopathology</i> , 2013, 62, 876-893.	2.9	12

#	ARTICLE	IF	CITATIONS
451	Biosimilar monoclonal antibodies in lymphoma: a critical appraisal. Expert Review of Anticancer Therapy, 2015, 15, 569-578.	2.4	12
452	Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70) Tj ETQq0 0 Q rgBT /Overlock 10 T	1.3	12
453	SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma. Annals of Hematology, 2018, 97, 123-131.	1.8	12
454	Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study. Journal of Cancer Research and Clinical Oncology, 2022, 148, 975-984.	2.5	12
455	Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas. American Journal of Surgical Pathology, 2022, 46, 58-70.	3.7	12
456	Single 4-Dose Rituximab Treatment for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with a Follow-Up (F/Up) of at Least 5 Years.. Blood, 2004, 104, 585-585.	1.4	12
457	Addition of Rituximab Improves Outcome of HIV Negative Patients with Burkitt Lymphoma Treated with the Lmba Protocol: Results of the Randomized Intergroup (GRAALL-Lysa) LMBA02 Protocol. (IGR) Tj ETQq1 1 0.7843.14 rgBT /Overlock 1	1.4	12
458	Results of a Phase Ib Study of Venetoclax Plus R- or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma. Blood, 2016, 128, 3032-3032.	1.4	12
459	First Analysis of an International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL Treated with R-CHOP in First Line, the Remarc Study from Lysa. Blood, 2016, 128, 471-471.	1.4	12
460	Phase 2 multi-center study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology, 2016, 34, TPS7582-TPS7582.	1.6	12
461	Randomized phase III study comparing an early PET driven treatment de-escalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma: Final analysis of the AHL2011 LYSA study.. Journal of Clinical Oncology, 2018, 36, 7503-7503.	1.6	12
462	Identification of Two Lymphotoxin Beta Isoforms Expressed in Human Lymphoid Cell Lines and Non-Hodgkin's Lymphomas. Biochemical and Biophysical Research Communications, 1997, 238, 273-276.	2.1	11
463	Identification and validation of seven genes, as potential markers, for the differential diagnosis of small B cell lymphomas (small lymphocytic lymphoma, marginal zone B cell lymphoma and mantle cell) Tj ETQq1 1 0.784314 rgBT /Ov	1.3	11
464	Haplotype-specific pattern of association of human major histocompatibility complex with non-Hodgkin's lymphoma outcome. Tissue Antigens, 2007, 71, 071029015950001-???	1.0	11
465	Marrow-ablative treatment and autologous stem cell transplantation in follicular NHL. Best Practice and Research in Clinical Haematology, 2011, 24, 257-270.	1.7	11
466	First immunochemotherapy outcomes in elderly patients with CLL: A retrospective analysis. Journal of Geriatric Oncology, 2013, 4, 141-147.	1.0	11
467	Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma. Blood, 2014, 123, 2740-2742.	1.4	11
468	POLA-R-CHP: POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA. Hematological Oncology, 2017, 35, 90-91.	1.7	11

#	ARTICLE	IF	CITATIONS
469	What Does This Mutation Mean? The Tools and Pitfalls of Variant Interpretation in Lymphoid Malignancies. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1251.	4.1	11
470	Human herpesvirus 6 infection after autologous stem cell transplantation: A multicenter prospective study in adult patients. <i>Journal of Infection</i> , 2019, 79, 36-42.	3.3	11
471	The role of tazemetostat in relapsed/refractory follicular lymphoma. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110158.	2.5	11
472	Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20-containing chemoimmunotherapy (POD24).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7515-7515.	1.6	11
473	Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, , .	3.5	11
474	A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2012, 120, 56-56.	1.4	11
475	RE-MIND study: A propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8020-8020.	1.6	11
476	Upfront Consolidation Combining Yttrium-90 Ibritumomab Tiuxetan and High Dose Therapy with Stem-Cell Transplantation in Poor Risk Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2012, 120, 812-812.	1.4	11
477	Atypical cytogenetic presentation of t(11;14) in mantle cell lymphoma. <i>Haematologica</i> , 2005, 90, 1708-9.	3.5	11
478	<scp>CD</scp>180 overexpression in follicular lymphoma is restricted to the lymph node compartment. <i>Cytometry Part B - Clinical Cytometry</i> , 2016, 90, 433-439.	1.5	10
479	Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas. <i>Anti-Cancer Drugs</i> , 2017, 28, 341-349.	1.4	10
480	Absence of driver mutations in persistent polyclonal B-cell lymphocytosis with binucleated lymphocytes. <i>Blood</i> , 2017, 130, 1267-1269.	1.4	10
481	Array-CGH predicts prognosis in plasma cell post-transplantation lymphoproliferative disorders. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 221-230.	2.8	10
482	A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial. <i>Blood</i> , 2021, 137, 1019-1023.	1.4	10
483	Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1. <i>Advances in Therapy</i> , 2021, 38, 3266-3280.	2.9	10
484	Optimizing CAR T cell therapy in lymphoma. <i>Hematological Oncology</i> , 2021, 39, 104-112.	1.7	10
485	Idelalisib immune-related toxicity is associated with improved treatment response. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-6.	1.3	10
486	Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial. <i>Blood Cancer Journal</i> , 2021, 11, 147.	6.2	10

#	ARTICLE	IF	CITATIONS
487	Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205). <i>Blood</i> , 2020, 136, 43-44.	1.4	10
488	10 Years Follow-up of the GELA LNH98.5 Study, First Randomized Study Comparing R-CHOP to CHOP Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2009, 114, 3741-3741.	1.4	10
489	Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2013, 122, 85-85.	1.4	10
490	Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2014, 124, 1708-1708.	1.4	10
491	An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma or Follicular Lymphoma. <i>Blood</i> , 2014, 124, 1718-1718.	1.4	10
492	Addition of High-Dose Cytarabine to Immunochemotherapy before Autologous Stem-Cell Transplantation in Patients Aged 65 Years or Younger with Mantle Cell Lymphoma (MCL Younger): A Long-Term Follow-up of the Randomized, Open-Label, Phase 3 Trial of the European Mantle Cell Lymphoma Network. <i>Blood</i> , 2021, 138, 380-380.	1.4	10
493	Tumor necrosis factor-alpha mRNA stability in human peripheral blood cells after lipopolysaccharide stimulation. <i>European Cytokine Network</i> , 2002, 13, 92-8.	2.0	10
494	CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2022, 63, 751-754.	1.3	10
495	Pregnancy and multiple myeloma are not antinomic. <i>Leukemia and Lymphoma</i> , 2013, 54, 2738-2741.	1.3	9
496	Central nervous system involvement in chronic lymphocytic leukemia: uncommon manifestation with undefined therapeutic management. <i>Leukemia and Lymphoma</i> , 2014, 55, 1939-1941.	1.3	9
497	Rapamycin safeguards lymphocytes from DNA damage accumulation in vivo. <i>European Journal of Cell Biology</i> , 2016, 95, 331-341.	3.6	9
498	The ibrutinib B-cell proliferation inhibition is potentiated in vitro by dexamethasone: Application to chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2016, 47, 1-7.	0.8	9
499	<i>FCGR3A</i>/<i>2A</i> polymorphisms and diffuse large Bâ€cell lymphoma outcome treated with immunochemotherapy: a metaâ€analysis on 1134 patients from two prospective cohorts. <i>Hematological Oncology</i> , 2017, 35, 447-455.	1.7	9
500	Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?. <i>Annals of Hematology</i> , 2017, 96, 363-371.	1.8	9
501	Acute myeloid leukemia in the elderly (age 70 yr or older): longâ€term survivors. <i>European Journal of Haematology</i> , 2017, 98, 134-141.	2.2	9
502	Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1. <i>Oncology and Therapy</i> , 2019, 7, 121-130.	2.6	9
503	Earlyâ€onset severe infections in allogeneic hematopoietic stem cell transplantation recipients with graft failure. <i>American Journal of Hematology</i> , 2019, 94, E109-E111.	4.1	9
504	Single-agent ibrutinib in RESONATE-2â„¢ and RESONATEâ„¢ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2019, 98, 2749-2760.	1.8	9

#	ARTICLE	IF	CITATIONS
505	Resources-Stratified Guidelines for Classical Hodgkin Lymphoma. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1783.	2.6	9
506	A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the "Real world data in Lymphoma and survival in adults" (REALYSA) cohort. <i>BMC Public Health</i> , 2021, 21, 432.	2.9	9
507	Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 19-21.	1.4	9
508	90Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients. <i>Blood</i> , 2010, 116, 594-594.	1.4	9
509	A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma. <i>Blood</i> , 2013, 122, 4397-4397.	1.4	9
510	Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN Study. <i>Blood</i> , 2016, 128, 1217-1217.	1.4	9
511	RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R ²) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7500-7500.	1.6	9
512	The translocations t(6;18;11)(q24;q21;q21) and t(11;14;18)(q21;q32;q21) lead to a fusion of the API2 and MALT1 genes and occur in MALT lymphomas. <i>Haematologica</i> , 2007, 92, 405-409.	3.5	9
513	Histologic transformation in follicular lymphoma. <i>Annals of Oncology</i> , 1998, 9, 803-805.	1.2	8
514	A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin's lymphoma and two or three adverse prognostic factors. <i>Leukemia</i> , 2000, 14, 2159-2165.	7.2	8
515	Improving Cancer Patient Care with Combined Medication Error Reviews and Morbidity and Mortality Conferences. <i>Chemotherapy</i> , 2013, 59, 330-337.	1.6	8
516	Obinutuzumab for chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2014, 7, 533-543.	2.2	8
517	PET-CT and diagnostic CT: The synergy of metabolic and morphological data in onco-haematology. <i>Diagnostic and Interventional Imaging</i> , 2014, 95, 55-62.	3.2	8
518	Chemotherapy-free treatment in patients with follicular lymphoma. <i>Expert Review of Hematology</i> , 2015, 8, 187-203.	2.2	8
519	The p16INK4A/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome. <i>Leukemia Research</i> , 2015, 39, 453-461.	0.8	8
520	Effect of Initial Body Mass Index on Survival Outcome of Patients With Acute Leukemia: A Single-Center Retrospective Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S7-S13.	0.4	8
521	Bone Marrow Necrosis in Newly Diagnosed Acute Leukemia: Two Case Reports and Review of the Literature. <i>Oncology and Therapy</i> , 2017, 5, 111-118.	2.6	8
522	VacHemInf project: protocol for a prospective cohort study of efficacy, safety and characterisation of immune functional response to vaccinations in haematopoietic stem cell transplant recipients. <i>BMJ Open</i> , 2019, 9, e026093.	1.9	8

#	ARTICLE	IF	CITATIONS
523	How do I sequence therapy for follicular lymphoma?. Hematology American Society of Hematology Education Program, 2020, 2020, 287-294.	2.5	8
524	Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Investigational New Drugs, 2020, 38, 1472-1482.	2.6	8
525	BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 267-278.e10.	0.4	8
526	Real-time targeted next-generation sequencing for lymphoma diagnosis over 1 year from the French Lymphoma Network. British Journal of Haematology, 2021, 193, 1110-1122.	2.5	8
527	Relapsed/Refractory International Prognostic Index (R ² -IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma. American Journal of Hematology, 2021, 96, 599-605.	4.1	8
528	Non-cryopreserved hematopoietic stem cells in autograft patients with lymphoma: a matched-pair analysis comparing a single center experience with the use of cryopreserved stem cells reported to the European Society for Blood and Marrow Transplantation registry. Cytotherapy, 2021, 23, 483-487.	0.7	8
529	Desynchronization of the Germinal Center Dynamics and Remodeling of the Tumor Microenvironment Characterize KMT2D-Driven Lymphomagenesis. Blood, 2018, 132, 670-670.	1.4	8
530	Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL). Blood, 2019, 134, 242-242.	1.4	8
531	Retreatment With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in ZUMA-5. Blood, 2020, 136, 34-34.	1.4	8
532	Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study. Blood, 2013, 122, 764-764.	1.4	8
533	A Phase Ib Study of Obinutuzumab Combined with Lenalidomide for Relapsed/Refractory Follicular B-Cell Lymphoma. Blood, 2014, 124, 4458-4458.	1.4	8
534	Activity of Idelalisib in High-Risk Follicular Lymphoma with Early Relapse Following Front Line Immunochemotherapy. Blood, 2015, 126, 2744-2744.	1.4	8
535	Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 183-183.	1.4	8
536	Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma. Blood Advances, 2022, 6, 2536-2547.	5.2	8
537	The detection of bone marrow involvement in small-cell lung cancer using magnetic resonance imaging.. Journal of Clinical Oncology, 1988, 6, 397-398.	1.6	7
538	Characterization of germinal center dendritic cells in follicular lymphoma. Experimental Hematology, 1999, 27, 1768-1775.	0.4	7
539	Epstein-Barr Virus-induced Lymphoproliferative Disorder After Rituximab Combined with CHOP Therapy. Clinical Lymphoma and Myeloma, 2008, 8, 356-358.	1.4	7
540	Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2. Annals of Oncology, 2008, 19, 560-565.	1.2	7

#	ARTICLE	IF	CITATIONS
541	Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA). <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 939-948.	2.3	7
542	Case report. <i>Medicine (United States)</i> , 2018, 97, e9657.	1.0	7
543	Acute renal and splenic infarctions: a review. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2020, 113, 186-193.	0.5	7
544	Immunosuppression medication adherence after allogeneic hematopoietic stem cell transplant: Impact of a specialized clinical pharmacy program. <i>Journal of Oncology Pharmacy Practice</i> , 2021, , 107815522110001.	0.9	7
545	Sub-Cutaneous Rituximab-Minichop Versus Sub-Cutaneous Rituximab-Minichop + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More (SENIOR Study). a Multicentric Randomized Phase III Study of the Lysa. <i>Blood</i> , 2019, 134, 352-352.	1.4	7
546	Long Term Results of the GELA Study, R-CHOP vs. CHOP in Elderly Patients with Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2004, 104, 1383-1383.	1.4	7
547	Result of FDG PET-CT Imaging After Immunochemotherapy Induction Is a Powerful and Independent Prognostic Indicator of Outcome for Patients with Follicular Lymphoma: An Analysis From the PRIMA Study. <i>Blood</i> , 2010, 116, 855-855.	1.4	7
548	Obinutuzumab (GA101) in Combination with FC or CHOP in Patients with Relapsed or Refractory Follicular Lymphoma: Final Results of the Phase I GAUDI Study (BO21000). <i>Blood</i> , 2011, 118, 270-270.	1.4	7
549	The Brutonâ€™s Tyrosine Kinase (BTK) Inhibitor ONO-4059: Promising Single Agent Activity and Well Tolerated in Patients with High Risk Chronic Lymphocytic Leukaemia (CLL). <i>Blood</i> , 2014, 124, 3328-3328.	1.4	7
550	A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies. <i>Blood</i> , 2014, 124, 4417-4417.	1.4	7
551	Novel Agents May be Preferable to Chemotherapy for Large B-Cell Lymphoma Progressing after CD19-CAR-T: A Multicenter Observational Study. <i>Blood</i> , 2021, 138, 883-883.	1.4	7
552	The expression of TCR-gamma delta/CD3 complex in neoplastic gamma delta T-cell. <i>Haematologica</i> , 2006, 91, 1717-9.	3.5	7
553	A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL). <i>HemaSphere</i> , 2022, 6, e745.	2.7	7
554	The host-tumor interface in B-cell non-Hodgkin lymphoma: A new world to investigate. <i>Current Hematologic Malignancy Reports</i> , 2009, 4, 196-201.	2.3	6
555	Is There a Role for Bortezomib Combinations in the Management of Patients With Follicular Lymphoma?. <i>Journal of Clinical Oncology</i> , 2011, 29, 3349-3350.	1.6	6
556	Actinomycosis after allogeneic hematopoietic stem cell transplantation despite penicillin prophylaxis. <i>Transplant Infectious Disease</i> , 2016, 18, 595-600.	1.7	6
557	Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries. <i>Leukemia and Lymphoma</i> , 2018, 59, 2113-2120.	1.3	6
558	Genetically Determined Height and Risk of Non-hodgkin Lymphoma. <i>Frontiers in Oncology</i> , 2019, 9, 1539.	2.8	6

#	ARTICLE	IF	CITATIONS
559	The use of tafasitamab in diffuse large B-cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110274.	2.5	6
560	Early progression of disease in follicular lymphoma is a robust correlate but not a surrogate for overall survival. <i>Blood Advances</i> , 2021, 5, 1729-1732.	5.2	6
561	Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma. <i>Haematologica</i> , 2022, 107, 1144-1152.	3.5	6
562	The Poor Prognosis Value of High Intra-Tumoral Macrophages Counts in Follicular Lymphoma Patients Requires Selection of Appropriate Cut-Off and Can Be Circumvented by Rituximab Therapy.. <i>Blood</i> , 2006, 108, 822-822.	1.4	6
563	Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - A New Standard in Therapy?.. <i>Blood</i> , 2007, 110, 390-390.	1.4	6
564	Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - Moving Forward to a First Standard of Care: Results From a Prospective International Multicenter Trial.. <i>Blood</i> , 2009, 114, 100-100.	1.4	6
565	Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients – First Results From a Phase II Study In Patients with Relapsed/Refractory DLBCL and MCL. <i>Blood</i> , 2010, 116, 2878-2878.	1.4	6
566	Integrated Analysis of High-Resolution Gene Expression and Copy Number Profiling Identified Biallelic Deletion of CDKN2A/2B Tumor Suppressor Locus As the Most Frequent and Unique Genomic Abnormality in Diffuse Large B-Cell Lymphoma (DLBCL) with Strong Prognostic Value in Both GCB and ABC Subtypes and Not Overcome by a Dose-Intensive Immunochemotherapy Regimen Plus Rituximab. Results of a Prospective GELA Clinical Trial Program. <i>Blood</i> , 2012, 120, 415-415.	1.4	6
567	Lenalidomide In Combination With R-CHOP (R2-CHOP) In Patients With High Burden Follicular Lymphoma: Phase 2 Study. <i>Blood</i> , 2013, 122, 248-248.	1.4	6
568	Role Of High-Dose Cytarabine and Total Body Irradiation Conditioning before Autologous Stem Cell Transplantation In Mantle Cell Lymphoma - A Comparison Of Nordic MCL2, HOVON 45, and European MCL Younger Trials. <i>Blood</i> , 2013, 122, 3367-3367.	1.4	6
569	Updated Safety and Preliminary Efficacy Data from a Phase 1b Study Combining Venetoclax (GDC-0199,) Tj ETQq1 1 0.784314 rgBT /Dv Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 829-829.	1.4	6
570	Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 7536-7536.	1.6	6
571	Identification of a novel e8/a4 BCR/ABL fusion transcript in a case of a transformed Sezary syndrome. <i>Haematologica</i> , 2007, 92, 1277-1278.	3.5	6
572	Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation: Phase II, Investigator-Initiated, Single-Center Study. <i>Blood</i> , 2020, 136, 11-12.	1.4	6
573	Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas. <i>Blood Reviews</i> , 2022, 56, 100988.	5.7	6
574	Modulation of Costimulatory Molecules on Follicular Lymphoma Cells by TNF and CD40. <i>Leukemia and Lymphoma</i> , 1999, 33, 331-341.	1.3	5
575	<sc>S</sc>tatin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: <sc>A</sc>n exploratory analysis of the PRIMA cohort study. <i>American Journal of Hematology</i> , 2016, 91, 410-415.	4.1	5
576	Unexpected cross-reactivity of anti-cathepsin B antibodies leads to uncertainties regarding the mechanism of action of anti-CD20 monoclonal antibody GA101. <i>Leukemia Research</i> , 2017, 55, 41-48.	0.8	5

#	ARTICLE	IF	CITATIONS
577	Cat-Scratch Disease. <i>Clinical Nuclear Medicine</i> , 2017, 42, 106-107.	1.3	5
578	Comprehensive analysis of a myeloperoxidase-negative acute promyelocytic leukemia. <i>Blood</i> , 2017, 129, 128-131.	1.4	5
579	Research protocol on early palliative care in patients with acute leukaemia after one relapse. <i>BMJ Supportive and Palliative Care</i> , 2017, 7, 480-484.	1.6	5
580	Refractory diffuse large B-cell lymphoma after first-line immuno-CT: Treatment options and outcomes. <i>Hematological Oncology</i> , 2018, 36, 533-542.	1.7	5
581	Elderly Patients (Age 70 Years or Older) With Secondary Acute Myeloid Leukemia or Acute Myeloid Leukemia Developed Concurrently to Another Malignant Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e211-e218.	0.4	5
582	Interim Update from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S278-S279.	0.4	5
583	Extracorporeal cytokine adsorption for treating severe refractory cytokine release syndrome (CRS). <i>Bone Marrow Transplantation</i> , 2020, 55, 2052-2055.	2.4	5
584	Adverse outcome in follicular lymphoma is associated with <i>MYC</i> rearrangements but not <i>MYC</i> extra copies. <i>British Journal of Haematology</i> , 2021, 194, 382-392.	2.5	5
585	Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study. <i>Blood</i> , 2018, 132, 4097-4097.	1.4	5
586	Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2019, 134, 4006-4006.	1.4	5
587	Rituximab Given after High Dose Therapy and Autologous Stem Cell Transplantation Induces Durable Clearance of Minimal Residual Disease in about Half of the Patients with Follicular Non Hodgkin's Lymphoma : 36 Months Results of a Multicenter Open Label Phase II Trial (M39012 Trial).. <i>Blood</i> , 2004, 104, 747-747.	1.4	5
588	Characteristics of Refractory and Relapsing Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2008, 112, 2589-2589.	1.4	5
589	R-ACVBP Benefits to Younger Patients with Non-Germinal Centre Diffuse Large B-Cell Lymphoma As Compared to R-CHOP in the GELA Trial LNH03-2B. <i>Blood</i> , 2011, 118, 2632-2632.	1.4	5
590	An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL). <i>Blood</i> , 2015, 126, 1493-1493.	1.4	5
591	Response to Rituximab Induction Is a Predictive Biomarker in Post-Transplant Lymphoproliferative Disorder (PTLD) and Allows Successful Treatment Stratification in an International Phase II Trial Including 152 Patients. <i>Blood</i> , 2015, 126, 816-816.	1.4	5
592	Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study. <i>Blood</i> , 2016, 128, 1853-1853.	1.4	5
593	The Bruton's tyrosine kinase (BTK) inhibitor ONO-4059: Single-agent activity in patients with relapsed and refractory non-GCB-DLBCL.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8553-8553.	1.6	5
594	Phase 1b study of venetoclax plus R- or G-CHOP in patients with B-cell non-Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7566-7566.	1.6	5

#	ARTICLE	IF	CITATIONS
595	Single or Tandem Autologous Stem-Cell Transplantation Given According to Prognostic Factors at Relapse for Hodgkin Lymphoma.. Blood, 2005, 106, 2069-2069.	1.4	5
596	Long Term Efficacy of Rituximab in B-Cell Post Transplantation Lymphoproliferative Disorders (B-PTLD): Update of the Multicenter, Open Label, Phase II Trial (M39037 TRIAL).. Blood, 2006, 108, 2764-2764.	1.4	5
597	Efficacy of Ibrutinib-Rituximab versus Real-World (RW) Treatments for Patients with Waldenström's Macroglobulinemia (WM): Adjusted Comparison of iNOVATE and the Lyon-Sud RW Database. Blood, 2018, 132, 1604-1604.	1.4	5
598	Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL). Blood, 2021, 138, 306-306.	1.4	5
599	Comparison Study for Genotyping of a Single-Nucleotide Polymorphism in the Tumor Necrosis Factor Promoter Gene. Diagnostic Molecular Pathology, 2002, 11, 228-233.	2.1	4
600	Systemic mastocytosis: Predictable factors of poor prognosis present at the onset of the disease. European Journal of Internal Medicine, 2005, 16, 387-390.	2.2	4
601	Detailed characterization of 7q deletions by multicolor banding (mBAND) in marginal zone cell lymphoma. Cancer Genetics and Cytogenetics, 2007, 175, 159-165.	1.0	4
602	Impact of rituximab on stem cell mobilization following ACVBP regimen in poor-risk patients with diffuse large B-cell lymphoma: results from a large cohort of patients. Transfusion, 2013, 53, 115-122.	1.6	4
603	Baseline differential blood count and prognosis in CD20-positive post-transplant lymphoproliferative disorder in the prospective PTL-1 trial. Leukemia, 2013, 27, 2102-2105.	7.2	4
604	FDG PET/CT Findings in Abdominal Fat Necrosis After Treatment for Lymphoma. Clinical Nuclear Medicine, 2016, 41, 397-398.	1.3	4
605	Idelalisib. Cancer Journal (Sudbury, Mass), 2016, 22, 12-16.	2.0	4
606	Systematic review of the recent evidence for the efficacy and safety of chlorambucil in the treatment of B-cell malignancies. Leukemia and Lymphoma, 2016, 57, 852-865.	1.3	4
607	Ibrutinib-Induced Lymphocytosis: Cytological Features. Acta Haematologica, 2017, 137, 55-57.	1.4	4
608	Diffuse Subcutaneous Fat Involvement in a Marginal Zone Lymphoma. Clinical Nuclear Medicine, 2017, 42, 129-130.	1.3	4
609	Definition of a minimal genes set for mature lymphoid blood diseases. Hematologie, 2018, 24, 27-59.	0.0	4
610	PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors. Annals of Oncology, 2018, 29, viii20.	1.2	4
611	Chronic Borrelia burgdorferi infection triggers NKT lymphomagenesis. Blood, 2018, 132, 2691-2695.	1.4	4
612	Metagenomic Investigation of Torque Teno Mini Virus-SH in Hematological Patients. Frontiers in Microbiology, 2019, 10, 1898.	3.5	4

#	ARTICLE	IF	CITATIONS
613	Efficiency of blinatumomab in a t(8;21) acute myeloid leukemia expressing CD19. <i>Haematologica</i> , 2019, 104, e487-e488.	3.5	4
614	Parameters influencing the pharmacokinetics/pharmacodynamics of piperacillin/tazobactam in patients with febrile neutropenia and haematological malignancy: a prospective study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2676-2680.	3.0	4
615	Prolonged Improvement in Patient Reported Quality of Life (QoL) Following Tisagenlecleucel Infusion in Adult Patients (pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL): 19-Month Follow-up (FU) of the Juliet Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S181-S182.	2.0	4
616	POLARIX: A PHASE 3 STUDY OF POLATUZUMAB VEDOTIN (POLA) PLUS R-CHP VERSUS R-CHOP IN PATIENTS (PTS) WITH UNTREATED DLBCL. <i>Hematological Oncology</i> , 2019, 37, 68-70.	1.7	4
617	Early Off-Study Experience of Chimeric Antigen Receptor T Cells in Aggressive Lymphoma: Closer to a Real-World Setting. <i>Journal of Clinical Oncology</i> , 2020, 38, 3085-3087.	1.6	4
618	LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A "REAL-LIFE" STUDY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020020.	1.3	4
619	Impact of using leader primers for IGHV mutational status assessment in chronic lymphocytic leukemia. <i>Leukemia</i> , 2020, 34, 2257-2259.	7.2	4
620	Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. <i>Blood Advances</i> , 2021, 5, 1737-1745.	5.2	4
621	Chronic T cell receptor stimulation unmasks NK receptor signaling in peripheral T cell lymphomas via epigenetic reprogramming. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	4
622	Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma. <i>European Journal of Cancer</i> , 2021, 157, 132-139.	2.8	4
623	Abstract LB-272: Genome-wide association study identifies multiple susceptibility loci for diffuse large B-cell lymphoma. <i>Cancer Research</i> , 2014, 74, LB-272-LB-272.	0.9	4
624	Avadomide (CC-122), a Novel Cereblon Modulating Agent, in Combination with Obinutuzumab (GA101) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 449-449.	1.4	4
625	Results of a Phase 3 Randomised Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Not Eligible for Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 4189-4189.	1.4	4
626	The Burden of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Systematic Literature Review (SLR). <i>Blood</i> , 2018, 132, 2241-2241.	1.4	4
627	Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind. <i>Blood</i> , 2018, 132, 227-227.	1.4	4
628	Atezolizumab in Combination with Obinutuzumab and Lenalidomide Demonstrates Favorable Activity and Manageable Toxicity in Patients with Relapsed/Refractory Follicular Lymphoma (FL): An Interim Analysis of a Phase Ib/II Trial. <i>Blood</i> , 2018, 132, 1603-1603.	1.4	4
629	Health-Related Quality of Life in Patients with Advanced-Stage Follicular Lymphoma Receiving Consolidation with 90Y-Ibritumomab Tiuxetan (Zevalin®) of First Remission: Results from the Randomized Phase 3 First-Line Indolent Trial (FIT).. <i>Blood</i> , 2007, 110, 3319-3319.	1.4	4
630	Germinal Center Phenotype Determined by Immunohistochemistry on Tissue Microarray Does Not Correlate with Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy in the Randomized Trial LNH98-5. A GELA Study.. <i>Blood</i> , 2007, 110, 51-51.	1.4	4

#	ARTICLE	IF	CITATIONS
631	Complete Remission After First-Line Radio Plus Chemotherapy Is Enough to Improve Survival in Extra Nodal NK/T Cell Lymphoma. <i>Blood</i> , 2011, 118, 2679-2679.	1.4	4
632	Pattern of Cytokine Release in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab and Possible Relationship with Development of Infusion Related Reactions (IRR). <i>Blood</i> , 2014, 124, 4674-4674.	1.4	4
633	Quantitative Assessment of Circulating Clonal IG-VDJ Sequences in Plasma of Follicular Lymphoma at Diagnosis Is Highly Predictive of Progression Free Survival (PFS). <i>Blood</i> , 2015, 126, 2675-2675.	1.4	4
634	Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2015, 126, 2743-2743.	1.4	4
635	A Phase II LYSA Study of Obinutuzumab Combined with Lenalidomide for Relapsed or Refractory Aggressive B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 4202-4202.	1.4	4
636	Genetic Polymorphisms in the Tumor Necrosis Factor Locus Influence Non-Hodgkin's Lymphoma Outcome. <i>Blood</i> , 1998, 91, 3574-3581.	1.4	4
637	Toll-like receptor expression and function differ between splenic marginal zone B cell lymphoma and splenic diffuse red pulp B cell lymphoma. <i>Oncotarget</i> , 2018, 9, 23589-23598.	1.8	4
638	No Increased Risk of Secondary Neoplasms in Patients Treated with Rituximab for Non-Hodgkin's Lymphoma : A Meta-Analysis of 9 Trials. <i>Blood</i> , 2014, 124, 1659-1659.	1.4	4
639	Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial. <i>Cancer Medicine</i> , 2022, 11, 61-73.	2.8	4
640	Hepatic angiosarcoma in a patient with essential thrombocythaemia and Budd-Chiari syndrome. <i>European Journal of Cancer</i> , 1995, 31, 423.	2.8	3
641	Towards new prognostic factors in diffuse large cell non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 1996, 7, 993-996.	1.2	3
642	Rituximab maintenance therapy for follicular lymphoma – Authors' reply. <i>Lancet</i> , The, 2011, 377, 1151-1152.	13.7	3
643	Interim Report from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor: Clinical Activity and Favorable Safety in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S380-S381.	0.4	3
644	Reply to H.J.A. Adams et al and E. Laffon et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 920-923.	1.6	3
645	Correlative Analyses of Cytokine Release Syndrome and Neurological Events in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S251-S252.	0.4	3
646	ABCL-170: Long-Term Outcomes from the Phase II L-MIND Study of Tafasitamab (MOR208) Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S267-S268.	0.4	3
647	Drug cost savings in phase III hematological oncology clinical trials in a university hospital. <i>Hematological Oncology</i> , 2020, 38, 576-583.	1.7	3
648	Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era. <i>Hematological Oncology</i> , 2020, 38, 137-145.	1.7	3

#	ARTICLE	IF	CITATIONS
649	Characteristics of T- and NK-cell Lymphomas After Renal Transplantation: A French National Multicentric Cohort Study. <i>Transplantation</i> , 2021, 105, 1858-1868.	1.0	3
650	Results from a Phase Ib Evaluation of Tazemetostat (EPZ-6438) in Combination with R-CHOP in Poor Prognosis Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): a Lysa Study. <i>Blood</i> , 2018, 132, 4191-4191.	1.4	3
651	Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the GadoIn Study. <i>Blood</i> , 2019, 134, 2822-2822.	1.4	3
652	A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 5310-5310.	1.4	3
653	Mutational Landscape of Grey Zone Lymphoma. <i>Blood</i> , 2019, 134, 21-21.	1.4	3
654	A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial. <i>Blood</i> , 2019, 134, 2877-2877.	1.4	3
655	Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial. <i>Blood</i> , 2019, 134, 1524-1524.	1.4	3
656	R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET. <i>Blood</i> , 2020, 136, 39-40.	1.4	3
657	Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response. <i>Blood</i> , 2020, 136, 47-49.	1.4	3
658	Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 46-47.	1.4	3
659	Factors Prognostic for Response and Event Free Survival and Treatment Related Toxicity in 306 Patients with Follicular or Mantle Cell Lymphoma Randomized to Single Agent Rituximab Given at the Standard or at a Prolonged Schedule.. <i>Blood</i> , 2004, 104, 588-588.	1.4	3
660	Analysis of IgVH, BCL-6, PIM, RHO/TTF and PAX5 Mutational Status in Splenic and Nodal Marginal Zone B Cell Lymphoma Suggests a Particular B Cell Origin.. <i>Blood</i> , 2005, 106, 162-162.	1.4	3
661	Autologous Stem Cell Transplantation (auto-SCT) as the Treatment of Choice for Follicular Lymphoma Patients in First Relapse: Final Analysis of the Outcome of 175 Patients Treated in the GELA/GOELAMS FL 2000 Study. <i>Blood</i> , 2008, 112, 773-773.	1.4	3
662	Rituximab maintenance for the Treatment of patients with Follicular Lymphoma: Systematic Review and Meta-Analysis of Randomized Trials - 2010 Update.. <i>Blood</i> , 2010, 116, 1798-1798.	1.4	3
663	Efficacy and Safety of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma: Results From a Phase I/II Study (BO20999). <i>Blood</i> , 2011, 118, 268-268.	1.4	3
664	MYC Gene Simple Hit Is a Strong Independent Predictive Factor of Survival in Diffuse Large B-Cell Lymphomas in Contrast to MYC Double-Hit Gene Alterations: A Study by the Groupe d'Etude Des Lymphomes De l'Adulte. <i>Blood</i> , 2012, 120, 541-541.	1.4	3
665	Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study. <i>Blood</i> , 2016, 128, 1102-1102.	1.4	3
666	Pseudo-Progression Among Patients with Follicular Lymphoma Treated with Ibrutinib in the Phase 2 DAWN Study. <i>Blood</i> , 2016, 128, 2980-2980.	1.4	3

#	ARTICLE	IF	CITATIONS
667	Ibrutinib in Association with R-DHAP/Ox for Patients with Relapsed/Refractory B-Cell Lymphoma: Preliminary Results of the Biblos Phase Ib Lysa Study. <i>Blood</i> , 2016, 128, 5384-5384.	1.4	3
668	Temporal Profiles of Lymphocyte Subsets and the Correlation with Infectious Events in Idelalisib-Treated Patients. <i>Blood</i> , 2016, 128, 5583-5583.	1.4	3
669	Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-Hodgkin lymphoma (iNHL).. <i>Journal of Clinical Oncology</i> , 2014, 32, e19554-e19554.	1.6	3
670	Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS7575-TPS7575.	1.6	3
671	A phase 3 study comparing polatuzumab vedotin plus R-CHP versus R-CHOP in patients with DLBCL (POLARIX).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS7589-TPS7589.	1.6	3
672	What Is the Best First-Line Treatment Strategy for Patients with Indolent Lymphomas?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 488-493.	3.8	3
673	Indolent Mantle Cell Lymphoma (MCL): A Retrospective Detailed Clinical and Morphological Analysis of 21 Patients, with Histological, Cytological, Cytogenetic, Interphase Genetic, Immunoglobulin Gene, and Gene Expression Profiling Analysis.. <i>Blood</i> , 2008, 112, 1780-1780.	1.4	3
674	EARLY Interim FDG-PET Scan in Localised Hodgkin Lymphoma: Evaluation of Practice in 5 French Centers. <i>Blood</i> , 2008, 112, 4935-4935.	1.4	3
675	Efficacy Comparison of Tisagenlecleucel Versus Standard of Care in Patients with Relapsed or Refractory Follicular Lymphoma. <i>Blood</i> , 2021, 138, 3528-3528.	1.4	3
676	Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance. <i>Blood</i> , 2021, 138, 2417-2417.	1.4	3
677	Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440). <i>Haematologica</i> , 2021, 106, 2834-2844.	3.5	3
678	Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program. <i>Cancers</i> , 2022, 14, 660.	3.7	3
679	Indolent lymphomas: introduction to a series highlighting progress and ongoing challenges. <i>Haematologica</i> , 2022, 107, 4-6.	3.5	3
680	A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma. <i>Blood Advances</i> , 2022, , .	5.2	3
681	Maintenance therapy in follicular lymphoma. <i>Current Opinion in Oncology</i> , 2011, 23, 449-454.	2.4	2
682	Pretreatment Levels of Vascular Endothelial Growth Factor in Plasma Predict a Complete Remission Rate and Time to Relapse or Progression in Patients with Diffuse Large B-Cell Lymphoma. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2013, 61, 165-174.	2.3	2
683	Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. <i>Oncolimmunology</i> , 2016, 5, e1186323.	4.6	2
684	Advances in the role of cytogenetic analysis in the molecular diagnosis of B-cell lymphomas. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 623-632.	3.1	2

#	ARTICLE	IF	CITATIONS
685	Impact of doxorubicin dose capping on the outcome of DLBCL patients with elevated body surface area. <i>Blood</i> , 2017, 129, 2811-2813.	1.4	2
686	Management of relapsed or refractory follicular lymphoma patients in daily practice â€“ a French non-interventional study. <i>Leukemia and Lymphoma</i> , 2018, 59, 2485-2488.	1.3	2
687	Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after <sc>FC</sc>-based first-line treatment: Retrospective observations from the <sc>FLO</sc> group. <i>American Journal of Hematology</i> , 2018, 93, E24-E27.	4.1	2
688	Predictive gene-expression score for follicular lymphoma â€“ Authors' reply. <i>Lancet Oncology</i> , The, 2018, 19, e282.	10.7	2
689	New drugs for old targets. <i>Hematological Oncology</i> , 2019, 37, 101-104.	1.7	2
690	BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). <i>Annals of Hematology</i> , 2019, 98, 1973-1980.	1.8	2
691	Impact of NPM1 mutation subtypes on treatment outcome in AML: The Lyon-University Hospital experience. <i>Leukemia Research</i> , 2019, 76, 29-32.	0.8	2
692	ABCL-135: RE-MIND: A Comparison of Tafasitamab (MOR208) + Lenalidomide (L-MIND) Versus Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S265-S266.	0.4	2
693	Antibody Therapy Maintenance in Follicular Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 689-699.	2.2	2
694	Obinutuzumab (G)-atezolizumab (atezo)-lenalidomide (len) for the treatment of relapsed/refractory (R/R) follicular lymphoma (FL): Final analysis of a phase Ib/II trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7511-7511.	1.6	2
695	ABCL-346: Overall Survival with Tafasitamab + Lenalidomide (LEN) vs Routinely Administered Therapies for ASCT-Ineligible Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the Observational RE-MIND2 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S392-S393.	0.4	2
696	Performances of Targeted RNA Sequencing for the Analysis of Fusion Transcripts, Gene Mutation, and Expression in Hematological Malignancies. <i>HemaSphere</i> , 2021, 5, e522.	2.7	2
697	Abstract CT110: Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). <i>Cancer Research</i> , 2018, 78, CT110-CT110.	0.9	2
698	A Phase II Lysa Study of Obinutuzumab Combined with Lenalidomide for Advanced Untreated Follicular B-Cell Lymphoma in Need of Systemic Therapy. <i>Blood</i> , 2018, 132, 446-446.	1.4	2
699	Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. <i>Blood</i> , 2018, 132, 922-922.	1.4	2
700	Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC). <i>Blood</i> , 2019, 134, 400-400.	1.4	2
701	Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 41-42.	1.4	2
702	Long Term Follow-Up Shows No Clinical Benefit for CD34+ Selection of Autologous Transplants Following Myeloablative Therapy in Patients with Newly Diagnosed Myeloma : An EBMT Phase III Randomized Study.. <i>Blood</i> , 2004, 104, 921-921.	1.4	2

#	ARTICLE	IF	CITATIONS
703	Significant Prognostic Impact of [18F]Fluorodeoxyglucose-PET Scan Performed During and At the End of Treatment with R-CHOP in High-Tumor Mass Follicular Lymphoma Patients: A GELA-GOELAMS Study. Blood, 2011, 118, 877-877.	1.4	2
704	Anti-Leukemic Activity of a Novel Pegylated Recombinant Erwinia Chrysanthemi-Derived L-Asparaginase On Lymphoid Cell Lines and Leukemia-Bearing Mouse Models.. Blood, 2012, 120, 2571-2571.	1.4	2
705	Recurrent Mutations of the Exportin 1 Gene (XPO1) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study. Blood, 2015, 126, 129-129.	1.4	2
706	A Multicenter, Case-Control Study Evaluating the Characteristics and Outcome of ITP Patients Refractory to, Rituximab, Splenectomy and Both TPO Receptor Agonists. Blood, 2015, 126, 3460-3460.	1.4	2
707	Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study. Blood, 2015, 126, 517-517.	1.4	2
708	Long-Term Follow-up with GS-4059, a Selective Irreversible BTK Inhibitor, in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia. Blood, 2016, 128, 3233-3233.	1.4	2
709	Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood, 1995, 86, 3257-3262.	1.4	2
710	Predictive value of FCGR3A genotype on response to rituximab induction and maintenance therapy (MT) in follicular non-Hodgkin's lymphoma (NHL).. Journal of Clinical Oncology, 2010, 28, 8065-8065.	1.6	2
711	An open-label phase II study of ibrutinib in patients with refractory follicular lymphoma.. Journal of Clinical Oncology, 2013, 31, TPS8614-TPS8614.	1.6	2
712	Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARE and MEducation) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 2020, 15, e0243309.	2.5	2
713	Infradiaphragmatic Hodgkin lymphoma: a large series of patients staged with PET-CT. Oncotarget, 2017, 8, 85110-85119.	1.8	2
714	Cost Effectiveness Analysis of Rituximab Maintenance In Patients with Untreated High Tumour Burden Follicular Lymphoma After Response to Immunochemotherapy: A UK National Healthcare Services Perspective.. Blood, 2010, 116, 3833-3833.	1.4	2
715	Abexinostat (S78454/PCI-24781), an Oral Pan-Histone Deacetylase (HDAC) Inhibitor in Patients with Refractory or Relapsed Hodgkin's Lymphoma, Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Results of a Phase I Dose-Escalation Study in 35 Patients. Blood, 2012, 120, 3643-3643.	1.4	2
716	Detection of Leukemic Phase in Patients with Follicular Lymphoma At Diagnosis: A Rare Event Associated with Poor Prognosis. Blood, 2012, 120, 1594-1594.	1.4	2
717	High CD34+ Cell Counts Decrease Hematologic Toxicity of Autologous Peripheral Blood Progenitor Cell Transplantation. Blood, 1998, 91, 3148-3155.	1.4	2
718	High Dose Therapy and Autologous Stem Cell Transplantation in Marginal Zone Lymphoma : An EBMT-FIL-Gimeto Retrospective Study. Blood, 2014, 124, 2526-2526.	1.4	2
719	A Retrospective Cohort Study of Treatment Outcomes of Adult Patients with Relapsed or Refractory Low-Grade Follicular Lymphoma (ReCORD-FL). Blood, 2021, 138, 1349-1349.	1.4	2
720	Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project. Blood, 2020, 136, 22-23.	1.4	2

#	ARTICLE	IF	CITATIONS
721	Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England. <i>Journal of Medical Economics</i> , 2022, 25, 730-740.	2.1	2
722	Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2â€”Technical). <i>Journal of Nuclear Medicine</i> , 2023, 64, 239-243.	5.0	2
723	Antiemetic activity of high-dose methylprednisolone associated with continuous-infusion metoclopramide and oral alprazolam during multiple-day chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 28, 77-79.	2.3	1
724	Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (cHL): randomized phase 3 KEYNOTE-204 study. <i>Annals of Oncology</i> , 2016, 27, vi327.	1.2	1
725	L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL) - A SINGLE-ARM PHASE II STUDY. <i>Hematological Oncology</i> , 2017, 35, 51-52.	1.7	1
726	New Treatment Options in Advanced Stage Follicular Lymphoma. <i>HemaSphere</i> , 2018, 2, e156.	2.7	1
727	Pattern of Care and Outcomes of Adolescent and Young Adults with Lymphoma Treated in the RhÃ¢ne-Alpes Region. <i>Journal of Adolescent and Young Adult Oncology</i> , 2019, 8, 684-696.	1.3	1
728	Reply to S. Fuji. <i>Journal of Clinical Oncology</i> , 2020, 38, 523-523.	1.6	1
729	Development of a Model for Chemical Screening Based on Collateral Sensitivity to Target BTK C481S Mutant. <i>Cancers</i> , 2020, 12, 901.	3.7	1
730	No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib. <i>Leukemia and Lymphoma</i> , 2021, 62, 837-845.	1.3	1
731	Non-Interventional Retrospective Multicenter Study Evaluating Real Word Idelalisib Use in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma Patients Enrolled in the French Early Access Program. <i>Blood</i> , 2018, 132, 5924-5924.	1.4	1
732	Safety and Efficacy of Venetoclax (VEN) in Combination with Bendamustine (B) Plus Rituximab (R) or Obinutuzumab (G) in Patients (pts) with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results from a Phase Ib Study (GO28440). <i>Blood</i> , 2018, 132, 1859-1859.	1.4	1
733	Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 1582-1582.	1.4	1
734	A French Multicentric Prospective Cohort of 6000 Patients with Integrative Epidemiological, Clinical, Biological and Treatment Data to Improve Knowledge on Outcome of Lymphoma Patients: Pilot Phase Results of the Real World Data in Lymphoma and Survival in Adults (REALYSA) Study. <i>Blood</i> , 2019, 134, 4762-4762.	1.4	1
735	PVAG Regimen (Prednisone, Vinblastine, Doxorubicin, Gemcitabine) Used in Real-Life Setting in First Line Therapy for Elderly Classical Hodgkin Lymphoma Patients: A Retrospective Study of Lysa Centers. <i>Blood</i> , 2020, 136, 11-11.	1.4	1
736	Diagnosis-to-Treatment Interval Is an Important Prognostic Factor with a Time-Dependent Effect Predicting Event-Free Survival after 12 Months from First-Line Treatment in Newly Diagnosed Diffuse Large B-Cell Primary CNS Lymphoma. <i>Blood</i> , 2020, 136, 43-45.	1.4	1
737	Efficacy of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with High-Risk Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the L-Mind Study. <i>Blood</i> , 2020, 136, 1-2.	1.4	1
738	Molecular Profiling of Diffuse Large B-Cell Lymphoma Identifies Robust Subtypes Including One Characterized by Host Inflammatory Response.. <i>Blood</i> , 2004, 104, 25-25.	1.4	1

#	ARTICLE	IF	CITATIONS
739	Maintenance Alemtuzumab in Refractory B-Cell Chronic Lymphocytic Leukemia Patients: Updated Data.. Blood, 2005, 106, 5032-5032.	1.4	1
740	Pharmacokinetics of RO5072759 (GA101) In Patients with Relapsed/Refractory CD20+ Malignant Disease (Phase I/II Study BO20999). Blood, 2010, 116, 1833-1833.	1.4	1
741	Comparison of Single Agent GA101 In Japanese and European Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL) – Results From Two Phase I Studies. Blood, 2010, 116, 4921-4921.	1.4	1
742	Expression of MYC, IgM, As Well As Non-Germinal Centre B-Cell Like Immunophenotype and Positive Immunofish Index Predict a Worse Progression Free Survival and Overall Survival in a Series of 670 De Novo Diffuse Large B-Cell Lymphomas Included in Clinical Trials: A GELA Study of the 2003 Program. Blood, 2012, 120, 1539-1539.	1.4	1
743	Early Stage Follicular Lymphoma: Is There a Clinical Impact of First Line Treatment?. Blood, 2012, 120, 2722-2722.	1.4	1
744	Mechanisms of Telomere Maintenance Dysfunction in B-Chronic Lymphocytic Leukemia Through CpG Island Methylation. Blood, 2012, 120, 3489-3489.	1.4	1
745	Rituximab and High-Dose Cytarabine Do Not Counteract the Adverse Prognostic Value of CDKN2A and TP53 Deletions in Autografted Mantle-Cell Lymphoma Patients. a European-MCL Network Study. Blood, 2014, 124, 1625-1625.	1.4	1
746	Tumoral Maximum Standardized Uptake Value > 10 Measured on 18 f-FDG-PET: A New Valid Marker to Discriminate Richter Syndrome. Blood, 2014, 124, 3306-3306.	1.4	1
747	Asparagine Synthetase Expression and L-Asparaginase Sensitivity in Aggressive Lymphomas. Blood, 2014, 124, 5494-5494.	1.4	1
748	Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of GS-4059 in Combination with Idelalisib in Subjects with B-Cell Malignancies. Blood, 2016, 128, 2961-2961.	1.4	1
749	Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): High Efficacy of High Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC auto-SCT). A Study of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT). Blood, 2016, 128, 514-514.	1.4	1
750	CHOP and DHAP plus rituximab followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): A pilot study from the GELA. Journal of Clinical Oncology, 2004, 22, 6529-6529.	1.6	1
751	A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).. Journal of Clinical Oncology, 2014, 32, TPS8620-TPS8620.	1.6	1
752	Long term toxicity and fatigue after treatment for non-Hodgkin lymphoma (NHL): An analysis of twelve collaborative lymphoma study association (LYSA) trials, the Simonal Study.. Journal of Clinical Oncology, 2016, 34, 7518-7518.	1.6	1
753	A phase 1/2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas (NHLs).. Journal of Clinical Oncology, 2016, 34, TPS7576-TPS7576.	1.6	1
754	L-mind: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large b-cell lymphoma (R-R DLBCL) – A single-arm phase II study.. Journal of Clinical Oncology, 2017, 35, 7514-7514.	1.6	1
755	Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional study. Cancer, 2021, , .	4.1	1
756	Gene Expression Profile Associated with Survival in Patients with Diffuse Large B-Cell Lymphoma Treated by Chemotherapy and Rituximab.. Blood, 2005, 106, 159-159.	1.4	1

#	ARTICLE	IF	CITATIONS
757	Impact of Reduced Dose Intensity for Elderly Patients with Diffuse Large B-CELL Lymphoma Receiving R-CHOP Every 14 or 21 Days: An Analysis of the LNH03â€“6B GELA Study.. Blood, 2012, 120, 2723-2723.	1.4	1
758	Follicular Lymphoma. , 2013, , 143-156.		1
759	A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study. Blood, 2013, 122, 76-76.	1.4	1
760	Pediatric ALL-like Therapy in Adults with T-Cell Lymphoblastic Lymphoma: Results of the Graall-Lysa LL03 Study. Blood, 2014, 124, 371-371.	1.4	1
761	Mutation Load and a Functional T Effector Signature May Distinguish Immunologically Distinct and Clinically Relevant Lymphoma Subsets. Blood, 2016, 128, 913-913.	1.4	1
762	A phase 1 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of MEDI7247 in patients with select relapsed/refractory hematologic malignancies.. Journal of Clinical Oncology, 2018, 36, TPS2603-TPS2603.	1.6	1
763	Ibrutinib in association with R-DHAP/ox for patients with relapsed/refractory b-cell lymphoma: Results of the escalating phase of the BIBLOS phase Ib LYSA study.. Journal of Clinical Oncology, 2018, 36, e19550-e19550.	1.6	1
764	Single-Agent Ibrutinib vs Real-World (RW) Treatments for Patients with Chronic Lymphocytic Leukemia (CLL) and del11q: Adjusted Comparison of RESONATE-2TM and RESONATE2TM with RW Databases. Blood, 2018, 132, 4427-4427.	1.4	1
765	Agressive Lymphomas. Hematologic Malignancies, 2019, , .	0.2	1
766	Combining Gene Expression Profiling and Artificial Intelligence to Diagnose B-Cell Non-Hodgkin Lymphoma. Blood, 2019, 134, 1476-1476.	1.4	1
767	Molecular and Genetic Characterization of Tumor Samples from Patients with Relapsed or Refractory Follicular Lymphoma Identifies Factors Influencing Response to Tazemetostat. Blood, 2021, 138, 1183-1183.	1.4	1
768	Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (HL). Blood, 2021, 138, 2447-2447.	1.4	1
769	Chromatin Accessibility Profiling to Increase Diagnostic Accuracy and Refine Cell-of-Origin Classification of Mature T-Cell Lymphomas. Blood, 2021, 138, 809-809.	1.4	1
770	TP53 and CD19-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma. Blood, 2021, 138, 710-710.	1.4	1
771	Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy. Blood, 2020, 136, 37-38.	1.4	1
772	Neoantigens in Patients with De Novo Follicular Lymphoma: Results from the PRIMA Study. Blood, 2020, 136, 25-26.	1.4	1
773	Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma. Blood Cancer Journal, 2022, 12, 29.	6.2	1
774	The EHA Research Roadmap: Malignant Lymphoid Diseases. HemaSphere, 2022, 6, e726.	2.7	1

#	ARTICLE	IF	CITATIONS
775	13 Diffuse large B-cell lymphoma. European Journal of Cancer, Supplement, 2010, 8, 8-9.	2.2	0
776	5.51 Is Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) in CLL Still Under Debate? A Population Matched Analysis Between Auto-HSCT and Rituximab-Fludarabine-Cyclophosphamide in First-Line CLL Patients. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S279-S280.	0.4	0
777	CNS prophylaxis in diffuse large B-cell lymphoma – Authors' reply. Lancet, The, 2012, 379, 1486-1487.	13.7	0
778	Treatment approaches to asymptomatic follicular lymphoma. Expert Review of Hematology, 2013, 6, 747-758.	2.2	0
779	Development of model for analysing respective collections of intended hematopoietic stem cells and harvests of unintended mature cells in apheresis for autologous hematopoietic stem cell collection. Transfusion and Apheresis Science, 2014, 50, 294-302.	1.0	0
780	PP.26.13. Journal of Hypertension, 2015, 33, e361.	0.5	0
781	PP.19.06. Journal of Hypertension, 2015, 33, e299.	0.5	0
782	Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma: Randomized phase 3 KEYNOTE-204 study. Annals of Oncology, 2016, 27, viii17.	1.2	0
783	Isolated hepatosplenic sarcoidosis: A pitfall for lymphoma evaluation by 18 F-FDG PET/CT. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2017, 36, 399-400.	0.0	0
784	[OP.4B.09] IMPORTANCE OF CLINIC AND AMBULATORY BLOOD PRESSURES AS PREDICTORS OF DEVELOPMENT AND PROGRESSION OF DIABETIC KIDNEY DISEASE. Journal of Hypertension, 2017, 35, e40.	0.5	0
785	Biomarker analysis of patients with follicular lymphoma treated with ibrutinib in the phase 2 DAWN study. Hematological Oncology, 2017, 35, 210-211.	1.7	0
786	Report: LYSA 2016. Hematologie, 2017, 23, 4-4.	0.0	0
787	Authors'™ Reply. Journal of Molecular Diagnostics, 2018, 20, 266.	2.8	0
788	Tumor-infiltrating T lymphocytes and morphogenesis of follicular lymphoma – reply. Human Pathology, 2018, 72, 198-199.	2.0	0
789	Through the Glass Ceiling. Journal of Clinical Oncology, 2018, 36, 923-923.	1.6	0
790	Unclassifiable Isolated Monoclonal Lymphocytosis: Comprehensive Description of a Retrospective Cohort. Cancers, 2019, 11, 1495.	3.7	0
791	Unravelling Subtleties of Angioimmunoblastic T-Cell Lymphoma. Journal of Oncology Practice, 2019, 15, 147-148.	2.5	0
792	Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes. , 2021, 5, 200-217.		0

#	ARTICLE	IF	CITATIONS
793	O17-2 Tafasitamab + lenalidomide versus lenalidomide monotherapy in transplant-ineligible patients with R/R DLBCL (RE-MIND). <i>Annals of Oncology</i> , 2021, 32, S293.	1.2	0
794	MICROALBUMINURIA AND OTHER CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH RESISTANT HYPERTENSION. <i>Journal of Hypertension</i> , 2004, 22, S106.	0.5	0
795	PREDICTORS OF LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH RESISTANT HYPERTENSION. <i>Journal of Hypertension</i> , 2004, 22, S155.	0.5	0
796	CORRELATES OF QT-INTERVAL PARAMETERS IN PATIENTS WITH RESISTANT HYPERTENSION. <i>Journal of Hypertension</i> , 2004, 22, S151.	0.5	0
797	USEFULNESS OF QT-INTERVAL PARAMETERS FOR CARDIOVASCULAR RISK STRATIFICATION IN HYPERTENSIVE TYPE 2 DIABETIC PATIENTS. <i>Journal of Hypertension</i> , 2004, 22, S116.	0.5	0
798	In Vivo Purge with Rituximab before Harvest Does Not Alter the Graft nor the Hematologic Recovery after Transplant.. <i>Blood</i> , 2004, 104, 910-910.	1.4	0
799	Is Conventional Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) an Optimal Long-Term Strategy for Non Hodgkin Lymphomas: A Retrospective Study from 1987 to 2004.. <i>Blood</i> , 2004, 104, 3328-3328.	1.4	0
800	VH Gene Analysis in Splenic Marginal Zone Lymphoma Identifies Patients with Structurally Similar B Cell Receptors but Does Not Provide Prognostic Information.. <i>Blood</i> , 2006, 108, 2421-2421.	1.4	0
801	Pharmacogenetic Study in Hodgkin's Lymphomas, Impact of UGT1A1 on Prognosis.. <i>Blood</i> , 2006, 108, 2266-2266.	1.4	0
802	Efficacy and Safety of Once Weekly Epoetin Beta 30 000 IU in 691 Patients with Solid or Lymphoid Malignancies Receiving Chemotherapy: Results from the NAUTICA Study.. <i>Blood</i> , 2006, 108, 3758-3758.	1.4	0
803	Effectiveness of epoetin beta 30,000 UI once weekly (QW) for treatment of anemia in solid tumor patients under chemotherapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 19588-19588.	1.6	0
804	Distinct Expression Patterns of microRNAs in Activated B Cell (ABC) and Germinal Center B (GC) Subtypes of Diffuse Large B Cell Lymphoma (DLBCL).. <i>Blood</i> , 2007, 110, 562-562.	1.4	0
805	Major dispersion in etoposide systemic exposure in malignant lymphoma patients receiving BEAM high dose chemotherapy followed by ABMT: A multicentre study of the Groupe d'Etudes des Lymphomes de l'Adulte (GELA). <i>Journal of Clinical Oncology</i> , 2008, 26, 8537-8537.	1.6	0
806	Multiple Secondary Genetic Events Inducing Histologic Progression (HP) of Non-MALT Marginal Zone Lymphoma (MZL): An Integrated Genomic Analysis of Genome-Wide Copy-Number-Changes (CNC) and Transcriptomic Data.. <i>Blood</i> , 2008, 112, 1198-1198.	1.4	0
807	Gene Expression Profile Analysis According to Recurrent Gene Copy Number Abnormalities Defines a Diffuse Large B-Cell Lymphoma Subgroup Characterized by 9p21 Locus Deletion, Ribosome Machinery Deregulation and Poor Prognosis. A GELA Study. <i>Blood</i> , 2008, 112, 803-803.	1.4	0
808	Molecular Characterization of the T(14;18)(q32;q21) Involving the IGH Locus and the MALT1 Gene in MALT Lymphomas. <i>Blood</i> , 2008, 112, 4145-4145.	1.4	0
809	Mir-21 Is Over Expressed in Aggressive SMZL. <i>Blood</i> , 2008, 112, 624-624.	1.4	0
810	Lymphoma recurrence 5 years or more following diffuse large B-cell lymphoma: Clinical characteristics and outcome. <i>Journal of Clinical Oncology</i> , 2009, 27, 8562-8562.	1.6	0

#	ARTICLE	IF	CITATIONS
811	Lenalidomide in Combination with Melphalan and Dexamethasone in Patients with Newly-Diagnosed Light-Chain (AL)-Amyloidosis: a Multicenter Phase I/II Dose Escalation Study.. Blood, 2009, 114, 427-427.	1.4	0
812	Cancer chemotherapeutic error in hospitalized patients: Attributable damages and extra costs.. Journal of Clinical Oncology, 2010, 28, e19529-e19529.	1.6	0
813	A phase I study of escalating doses of lenalidomide combined with R-CHOP (R2-CHOP) for front-line treatment of B-cell lymphomas.. Journal of Clinical Oncology, 2010, 28, TPS297-TPS297.	1.6	0
814	Ãchos deÃ ASCO surÃ lymphomes. Hematologie, 2010, 16, 281-283.	0.0	0
815	Comparison of Clinical Characteristics, Plasma Cytokine Signature, Cytokine Gene Polymorphisms and Outcome Between EBV Positive and Negative Hodgkin Lymphoma: a Study of the Groupe Des Lymphomes De l'Adulte (GELA). Blood, 2010, 116, 3884-3884.	1.4	0
816	Obinutuzumab. Drugs of the Future, 2011, 36, 657.	0.1	0
817	FCGR3A and FCGR2A Polymorphisms Do Not Affect Response and Outcome of Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab and Chemotherapy. A Study Based on 554 Patients Included in GELA (Groupe d'Etude des Lymphomes de l'Adulte) Prospective Multicentric Study LNH2003. Blood, 2011, 118, 90-90.	1.4	0
818	Sequential Treatment with Rituximab Followed by CHOP Chemotherapy in Adult B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) - Establishing a New Standard of Care: Final Results From the Prospective International Multicenter PTL1 Trial. Blood, 2011, 118, 878-878.	1.4	0
819	Single Nucleotide Polymorphisms in ABCB1 and CBR1 Predict Toxicity to R-CHOP Type Regimens in Patients with Diffuse Non Hodgkin's Lymphoma. Blood, 2012, 120, 1616-1616.	1.4	0
820	P53 Prevents TCR-Dependent Peripheral T-Cell Lymphomagenesis From Chronically Stimulated T Cells.. Blood, 2012, 120, 2401-2401.	1.4	0
821	Lymphoma Occurring Over the Age of 90: Clinical Presentation and Outcome. Blood, 2012, 120, 1582-1582.	1.4	0
822	Absence of Prognostic Impact Associated with the Use of Statins in Patients with Follicular Lymphoma in the Rituximab Era: An Exploratory Analysis From the PRIMA Study.. Blood, 2012, 120, 2649-2649.	1.4	0
823	Autologous Stem Cell Transplantation (ASCT) for Enteropathy-Associated T-Cell Lymphoma (EATL): Final Analysis of a Retrospective Study On the Behalf of Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT).. Blood, 2012, 120, 3105-3105.	1.4	0
824	Expression of a Dysfunctional Activation Induced Cytidine Deaminase Is Correlated with Disease Progression in Splenic Marginal Zone Lymphoma.. Blood, 2012, 120, 2397-2397.	1.4	0
825	Low Serum Vitamin D Levels Are Associated with Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and Lysa Studies.. Blood, 2012, 120, 2712-2712.	1.4	0
826	Prognostic Value of Six Germline Single Nucleotide Polymorphisms At the REL, HLA-DRA, GATA3 and PVT1 Loci Identified in a Classical Hodgkin Lymphoma Genome-Wide Association Study: A Meta-Analysis of 601 Patients for Progression-Free Survival From Two Independent Studies. Blood, 2012, 120, 3637-3637.	1.4	0
827	Abstract 4055: Non-canonical telomere maintenance mechanism in B-cell chronic lymphocytic leukemia.. , 2013, , .		0
828	Iron Parameters and Relation To Prognosis In Elderly Patients With Aggressive Lymphoma Receiving First Line Immunochemotherapy: An Analysis Of The Lysa LNH 03-6B Study. Blood, 2013, 122, 2202-2202.	1.4	0

#	ARTICLE	IF	CITATIONS
829	Obinutuzumab (GA101) Plus CHOP Or FC In Relapsed/Refractory Follicular Lymphoma: Final Data From The Maintenance Phase Of The Phase 1b GAUDI Study (BO21000). <i>Blood</i> , 2013, 122, 1814-1814.	1.4	0
830	Toll-Like Receptor Profiles In Splenic Marginal Zone B-Cell Lymphoma and Splenic Diffuse Red Pulp B-Cell Lymphoma. <i>Blood</i> , 2013, 122, 3009-3009.	1.4	0
831	Prognostic Value Of Red Blood Cell and Platelet Transfusion In Elderly Patients With Aggressive Lymphoma Receiving First Line Immunochemotherapy: An Analysis Of The Lysa LNH 03-6B Study. <i>Blood</i> , 2013, 122, 3663-3663.	1.4	0
832	Circulating t(14;18)+ Cells As Predictive Markers Of Follicular Lymphoma Development. <i>Blood</i> , 2013, 122, 364-364.	1.4	0
833	Reappraisal Of The p16INK4A/Prb Pathway and Telomerase Activity, Markers Of Cell Activation and Aging, In Adult Acute Lymphoblastic Leukemia: A Graall Study. <i>Blood</i> , 2013, 122, 2579-2579.	1.4	0
834	BCL10 : rôle ambigu dans la cascade apoptotique et la tumorigenèse.. <i>Medecine/Sciences</i> , 1999, 15, 1469.	0.2	0
835	Prognostic value of PET-CT after frontline therapy in follicular lymphoma: A pooled analysis of central review in three multicenter studies.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8502-8502.	1.6	0
836	Meta-analysis of the risk of secondary neoplasm in patients treated for non-Hodgkin lymphoma with rituximab.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19541-e19541.	1.6	0
837	Individual Patient Data (IPD) Meta-Analysis of Rituximab Maintenance (MR) for Patients (pts) with Follicular Lymphoma (FL). <i>Blood</i> , 2014, 124, 4462-4462.	1.4	0
838	A New Prognostic Score for Patients Older Than 60 Years with a Classical Hodgkin Lymphoma: A Retrospective Analysis on 165 Patients. <i>Blood</i> , 2014, 124, 1721-1721.	1.4	0
839	Identification of Previously Unrecognized CD1d-Restricted Peripheral T Cell Lymphomas (PTCLs) in Mouse and Human Reveals Blocking Anti-CD1d Monoclonal Antibodies As a New Therapeutic Possibility in PTCLs. <i>Blood</i> , 2014, 124, 4485-4485.	1.4	0
840	Impact of Rituximab-Based Immunochemotherapy Induction and Maintenance on the Immunisation Rate Against Tetanus Toxin in Follicular Lymphoma Treated Patients : A Subanalysis of the PRIMA Study. <i>Blood</i> , 2014, 124, 4430-4430.	1.4	0
841	Long-Term Remission (>3 years) after Rituximab Monotherapy Used for Patients with Relapsed Indolent Non-Hodgkin Lymphomas (NHL). <i>Blood</i> , 2014, 124, 1709-1709.	1.4	0
842	Abstract 4810: Exome sequencing of refractory diffuse large B-cell lymphomas highlights candidate genes for targeted resequencing. , 2015, , .		0
843	Impact of 18 f-Fluoro-Deoxyglucose Positron Emission Tomography Imaging in the Management of Mantle Cell Lymphoma. <i>Blood</i> , 2015, 126, 3951-3951.	1.4	0
844	Inhibition of Hedgehog Signaling for the Treatment of Lymphoma and CLL: A Phase II Study from the Lysa. <i>Blood</i> , 2015, 126, 3970-3970.	1.4	0
845	Integrative Analysis of Diffuse Large B Cell Lymphoma Mutational Landscape: A Lysa Study. <i>Blood</i> , 2015, 126, 1472-1472.	1.4	0
846	Baseline Metabolic Tumour Volume Predicts Outcome in High Tumor Burden Follicular Lymphoma. A Pooled Analysis of Three Multicenter Studies. <i>Blood</i> , 2015, 126, 3919-3919.	1.4	0

#	ARTICLE	IF	CITATIONS
847	Prevalence and Prognostic Value of BCL2 and MYC Protein Expression within ABC and GCB Subtypes in Patients with Previously Untreated, Diffuse Large B-Cell Lymphoma: Analysis from the Phase III MAIN Study. <i>Blood</i> , 2015, 126, 3971-3971.	1.4	0
848	Idelalisib Treatment Is Associated with Improved Cytopenias in Patients with Relapsed/Refractory iNHL and CLL. <i>Blood</i> , 2015, 126, 1747-1747.	1.4	0
849	Management of transaminase elevations in patients receiving idelalisib.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7532-7532.	1.6	0
850	Classification of diffuse large b-cell lymphoma (DLBCL) FFPE samples of the GELA LNH2003 program, using Lymph2Cx assay on the nCounter analysis system.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7547-7547.	1.6	0
851	Allogeneic anti-CD19 CAR T cells: new perspectives in the treatment of B-cell malignancies that progress after allogeneic stem cell transplantation?. <i>Translational Cancer Research</i> , 2016, 5, S5-S8.	1.0	0
852	Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and Non-L265P Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases. <i>Blood</i> , 2016, 128, 4097-4097.	1.4	0
853	Integrated Analysis of IGHV Gene Status, Cell-of-Origin Signature and Genomic Features in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 4118-4118.	1.4	0
854	Incidence and Risk Factors for Central Nervous System Relapse in Very Elderly Patients over 80 with Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of Two Lysa Studies. <i>Blood</i> , 2016, 128, 927-927.	1.4	0
855	Fractionated Gemtuzumab Ozogamicin Combined with Intermediate-Dose Cytarabine and Daunorubicin As Salvage Therapy in Very High Risk AML Patients: A Bridge to Reduced Intensity Conditioning Transplant?. <i>Blood</i> , 2016, 128, 4003-4003.	1.4	0
856	Outcome Analysis of High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation in Patients with Hodgkin Lymphoma: A Francophone Society of Bone Marrow Transplantation and Cellular Therapy Study. <i>Blood</i> , 2016, 128, 3458-3458.	1.4	0
857	Genome-Wide Association Study of the Human Genetic Factors Influencing the Risk of Adverse Events during Idelalisib Therapy in Patients with Relapsed Indolent Lymphoma. <i>Blood</i> , 2016, 128, 5284-5284.	1.4	0
858	Evaluation of Immune Mechanisms to Understand Idelalisib-Associated Diarrhea-Colitis. <i>Blood</i> , 2016, 128, 5588-5588.	1.4	0
859	Early Human Herpes Virus 6 Infection after Autologous Stem Cell Transplantation: A Multicenter Prospective Observational Study of 196 Patients (VIRAUTO 6). <i>Blood</i> , 2016, 128, 3698-3698.	1.4	0
860	Single-Agent Ibrutinib Vs Standard of Care for Patients with Relapsed/Refractory (R/R) and Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): An Adjusted Comparison of RESONATE™ and RESONATE-2™ with the French Lyon-Sud Database. <i>Blood</i> , 2016, 128, 2039-2039.	1.4	0
861	Preliminary results of a phase Ib study of GS-4059 in combination with entospletinib in patients with B-cell malignancies.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7518-7518.	1.6	0
862	CheckMate 436: A phase 1-2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS7577-TPS7577.	1.6	0
863	The Biologic Interconnections Between Aging and Lymphoma. , 2018, , 1-12.		0
864	Abstract 4921: Population pharmacokinetic modeling of ibrutinib administered in patients with relapsed or refractory B cell malignancies eligible for autologous stem cell transplantation. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
865	Abstract 221: Inherited variants at 3q13.33 and 3p24.1 influences risk of diffuse large B-cell lymphoma. , 2018, , .		0
866	High Rate of Complete Response (CR) with Undetectable Bone Marrow Minimal Residual Disease (MRD) after Chemo-Sparing and MRD-Driven Strategy for Untreated Fit CLL Patients: Final Results of the Icll 07 Filo Trial. Blood, 2018, 132, 1858-1858.	1.4	0
867	A New Simplified Prognostic Index Integrating the Type of Extra-Nodal Involvement and Age for Ann Arbor Stage IV Hodgkin Lymphoma Patients Diagnosed at TEP-Scanner Era: A Retrospective Analysis from Lymphoma Study Association (LYSA) Centers. Blood, 2018, 132, 1629-1629.	1.4	0
868	Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Idelalisib in Patients with B-Cell Lymphoma. Blood, 2018, 132, 5345-5345.	1.4	0
869	Risk of Histological Transformation in Patients with Primary Refractory Follicular Lymphoma. Blood, 2018, 132, 4145-4145.	1.4	0
870	Identification of a Genetic Signature Enriching for Response to Ibrutinib in Relapsed/Refractory Follicular Lymphoma in the Dawn Phase 2 Trial. Blood, 2018, 132, 4147-4147.	1.4	0
871	Follicular Lymphoma Grade 3A Exhibits Pathological and Cytogenetic Diversity, but Similar Prognosis Compared to FL Grade 1-2: Pooled Analysis of 1757 Follicular Lymphomas from the PRIMA and Relevance Trials. Blood, 2018, 132, 778-778.	1.4	0
872	Impact of Total Metabolic Tumor Volume at Baseline in the Remarc Study. Blood, 2018, 132, 4199-4199.	1.4	0
873	Ritumixab in Combination with Adapted-Dose of Ifosfamide and Etoposide As Salvage Treatment in Elderly Refractory/Relapsed Diffuse Large B-Cell Lymphoma Patients Non-Candidate for High Dose Therapy: A Retrospective Study of Lyon Hospital University. Blood, 2018, 132, 4215-4215.	1.4	0
874	Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma. Blood, 2018, 132, 5344-5344.	1.4	0
875	Correction to: Aggressive Lymphomas. Technik Im Fokus, 2019, , C1-C1.	0.2	0
876	Individualized Prediction of Follicular Lymphoma Risk Using a Combination of Blood t(14;18) Frequency Years before Diagnosis and a Polygenic Risk Score (PRS) of 9 SNPs Associated with Follicular Lymphoma Susceptibility. Blood, 2019, 134, 2775-2775.	1.4	0
877	A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group. Blood, 2019, 134, 2812-2812.	1.4	0
878	Maintenance of Long-Term Undetectable Minimal Residual Disease after Combination of Ibrutinib with Abbreviated Chemotherapy in the Icll-07 Filo Trial. Blood, 2019, 134, 3038-3038.	1.4	0
879	Implication of Inherited Genetic Variants Associated with Follicular Lymphoma Susceptibility in the Prognosis of Patients Treated By Immunochemotherapy in PRIMA Study. Blood, 2019, 134, 2780-2780.	1.4	0
880	Molecular Characterisation of Diffuse Large B Cell Lymphoma in Patients of 80 Years Old or More: Clinical Relevance in a Multicentric Randomized Phase III Study of the Lysa (SENIOR Study). Blood, 2019, 134, 2765-2765.	1.4	0
881	Follicular lymphoma: twenty years of progress, and multiple challenges. Hematologie, 2019, 25, 2-2.	0.0	0
882	Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study. Leukemia and Lymphoma, 2022, 63, 599-607.	1.3	0

#	ARTICLE	IF	CITATIONS
883	The Biologic Interconnections Between Aging and Lymphoma. , 2020, , 141-152.		0
884	Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study. Blood, 2020, 136, 42-43.	1.4	0
885	Safety and Effectiveness of Idelalisib in Patients with Double-Refractory Follicular Lymphoma: A Pan-European Cohort of 242 Patients. Blood, 2021, 138, 1350-1350.	1.4	0
886	Impact of Choice of Platinum-Based Salvage Therapy on CNS Relapse in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 2529-2529.	1.4	0
887	Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance. Blood, 2021, 138, 5031-5031.	1.4	0
888	Quantitative Change in Metabolic Tumor Volume May Assist in Distinguishing between Pseudoprogressors and Responders in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Treated with PD-1 Blockade. Blood, 2021, 138, 1402-1402.	1.4	0
889	Clinical Outcomes and CNS Relapse Risk in Patients with Primary Cutaneous DLBCL, Leg Type Treated in the Rituximab Era: Long-Term Follow-up of a Single-Center Experience. Blood, 2021, 138, 2513-2513.	1.4	0
890	Favorable Outcomes of Patients with Limited-Stage Ocular Adnexal DLBCL Treated in the Rituximab Era: Long-Term Follow-up of a Single Center Experience. Blood, 2021, 138, 4578-4578.	1.4	0
891	Interviews of Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Lisocabtagene Maraleucel (liso-cel) Trials on Their Treatment Experience for 3 Months after Infusion. Blood, 2021, 138, 4098-4098.	1.4	0
892	Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study. Blood, 2020, 136, 34-35.	1.4	0
893	NON Cryopreserved Hematopoietic STEM CELLS to Autograft Patients with Lymphomas: A PAIR Matched Analysis Comparing a Single Center Experience to the Use of Cryopreserved STEM CELLS Reported to the EBMT Registry. Blood, 2020, 136, 20-21.	1.4	0
894	Safety Profile of Idelalisib in Patients with Refractory Follicular Lymphoma: Interim Analysis of a Noninterventional Study. Blood, 2020, 136, 48-50.	1.4	0
895	Estimation of Long-Term Survival with Tafasitamab + Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 9-10.	1.4	0
896	Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study. Blood, 2020, 136, 5-6.	1.4	0
897	Qualitative Analysis of the Treatment Experience and Well-Being of Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Trials of Lisocabtagene Maraleucel (liso-cel) during the Initial Stages of Therapy. Blood, 2020, 136, 22-23.	1.4	0
898	High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles. Blood, 2020, 136, 17-18.	1.4	0
899	Retrospective Evaluation of Rituximab, Methotrexate, Procarbazine, Vincristine and Etoposide Followed By Consolidation with Rituximab, Aracytine and Ifosfamide for Elderly Patients with Newly Diagnosed Primary CNS Lymphoma. Blood, 2020, 136, 6-7.	1.4	0
900	The upper ECHELON against T-cell lymphoma. Annals of Oncology, 2022, 33, 239-241.	1.2	0

#	ARTICLE	IF	CITATIONS
901	Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group. <i>Cancers</i> , 2022, 14, 1761.	3.7	0
902	PET-CT before autologous stem cell transplant in follicular lymphoma: coming too late?. <i>Haematologica</i> , 2022, , .	3.5	0
903	Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).. <i>Journal of Clinical Oncology</i> , 2022, 40, 7560-7560.	1.6	0
904	Abstract 5186: Higher levels of circulating exhausted T-cells at pre- and post-infusion negatively associated with clinical efficacy in tisagenlecleucel (Tisa-cel) treated relapsed/refractory large B-cell lymphoma (r/r LBCL) patients (pts) in JULIET trial. <i>Cancer Research</i> , 2022, 82, 5186-5186.	0.9	0